1

ALAN BERNSTEIN, O.C., PhD, FRSC, LL.D. (Hon) CURRICULUM VITAE

Executive Director: Global HIV Vaccine Enterprise 200 Park Avenue South, Suite 1501

New York, NY 10003 Tel: (212) 461-3692 / Fax: (212) 780-0607 E-mail: abernstein@vaccineenterprise.org

Education and Training: 1968 B.Sc., (Honours), University of Toronto, Mathematics and Physics. 1972 Ph.D., University of Toronto, Medical Biophysics. Supervisor: Dr. James E. Till. 1972-1974 Postdoctoral Fellow, Imperial Cancer Research Fund Laboratories, London, UK. Appointments: 1974-1979 Assistant Professor, Dept. of Medical Biophysics, University of Toronto 1974-1985 Staff Member, Division of Biological Research, Ontario Cancer Institute, Toronto 1979-1984 Associate Professor, Dept. of Medical Biophysics, University of Toronto 1984- Professor, Dept. of Medical Biophysics, University of Toronto 1985-1994 Head, Division of Molecular and Developmental Biology, Samuel Lunenfeld

Research Institute of Mount Sinai Hospital, Toronto 1986- Professor, Dept. of Medical Genetics and Microbiology, University of Toronto 1987- Member, Graduate Faculty, Institute of Medical Science, University of Toronto 1988-1994 Associate Director, Samuel Lunenfeld Research Institute of Mount Sinai Hospital,

Toronto 1994-2000 Director, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto 1995- Professor, Department of Medicine, Faculty of Medicine, University of Toronto 2000-2007 President, Canadian Institutes of Health Research, Ottawa 2008-2010 Honorary Research Fellow, School of Family & Public Health, Nelson Mandela

Faculty of Medicine, University of Kwazulu-Natal, Durban, South Africa Honours Received: 1965-1967 Special Council of Innis College Scholarship 1968 The Innis College Award 1968 The James Loudon Gold Medal of the American Association for the Advancement of

Science in Mathematics and Physics 1972-1973 The King George V Silver Jubilee Cancer Research Fellowship from the National

Cancer Institute of Canada 1985-1991 McLaughlin Scientist 1986 Joseph J. Schiffer Exchange Visitor to Israel 1987 MRC Visiting Professor, Queen's University Kingston, February, 1987 1990 First Incumbent, Anne Tanenbaum Chair in Molecular and Developmental Biology,

Samuel Lunenfeld Research Institute of Mount Sinai Hospital

2

1991 Fellow, Royal Society of Canada 1991-1996 International Research Scholar - Howard Hughes Medical Institute 1994-2000 The Koffler Chair for the Director, Samuel Lunenfeld Research Institute 1996 The 1996 Award of Merit, City of Toronto 1996 The McLaughlin Medal, The Royal Society of Canada 1997 The Robert L. Noble Award, National Cancer Institute of Canada 1998 The Genetics Society of Canada Award of Excellence 2000 The Canadian Society for Clinical Investigation/Royal College of Physicians and

Surgeons of Canada 2000 Henry Friesen Award 2000 The Inaugural Distinguished Science Leadership Lecture, B.C. Cancer Agency &

Vancouver General Hospital 2000 The Ottawa Life Sciences National Award of Merit 2001 The Australian Society for Medical Research Medal 2002 Award of Merit, Japan Society for the Promotion of Cancer Research 2002 Officer of the Order of Canada 2002 Queen Elizabeth II Jubilee Medal 2003 Guest of Honour, The Gairdner Foundation 2003 International Awards Dinner 2004 ‘Inspirational Innisian’, Innis College, University of Toronto 2004 Senior Fellow, Massey College, University of Toronto 2005 Member, The Canadian Academy of Health Sciences 2007 Doctor of Laws, honoris causa, Dalhousie University 2007 Médaille du mérite of the Institut de recherches cliniques de Montréal 2008 The Biotechnology Initiative Lifetime Achievement Award 2008 Health Charities Coalition of Canada Inaugural Award of Distinction 2008 Canadian Society of Biochemistry, Molecular and Cellular Biology Inaugural Arthur

Wynne Gold Medal 2008 Canadian Association of University Research Administrators, Walter Hitschfield

Award 2008 Gairdner Foundation Wightman Award 2009 Doctor of Science, honoris causa, University of British Columbia Key Lectures 1992 Second Allan J. Erslev Distinguished Lectureship, Jefferson Medical College,

Thomas Jefferson University, Philadelphia 1995 Leukaemia Research Fund (of Great Britain) Speaker, Cancer Research Campaign 1995 Thomson Lecturer - Department of Biochemistry at McGill University, Montreal 2001 Garner King Lecturer, Research Day, University of Alberta 2001 The Telstra Address, National Press Club, Canberra, Australia 2002 The Inaugural Lecturer, The Alan Bernstein Distinguished Lecture Series, The

McDonald Research Laboratories, University of British Columbia, Vancouver 2003 Keynote Address, Gairdner Foundation International Awards Gala, Toronto 2005 Inaugural Keynote Address, The Canadian Academy of Health Sciences, Vancouver Memberships in Scientific Societies:

3

1970- American Society for Microbiology 1977- Canadian Society for Cell Biology 1986- Genetics Society of Canada MEMBERSHIPS ON COMMITTEES FEDERAL BOARD MEMBERSHIPS: 2000-2007 Member, Canadian Health Services Research Foundation 2000-2007 Chair, Governing Council, Canadian Institutes of Health Research 2000-2007 Member, Board of Directors, Genome Canada 2000-2007 Health Canada Scientific Advisory Board 2000-2007 Steering Committee, Canada Research Chairs 2000-2007 Steering Committee, Networks of Centres of Excellence 2002-2004 Member, Board of Directors, Canada Foundation for Innovation 2002-2007 Associate Member, Natural Sciences & Engineering Research Council of Canada 2003-2007 Member, Prime Minister’s Advisory Committee on Science and Technology 2005-2007 Chair, Steering Committee, Canada Research Chairs BOARD MEMBERSHIPS (SELECTION): 1982 Member, Search Committee, Head, Division of Biological Research, Ontario Cancer Institute 1984 Member, Executive Committee, Division of Biological Research, Ontario Cancer Institute1982-1984 Member, Research Advisory Group, National Cancer Institute of Canada 1984-1986 Member, Advisory Committee on Research, National Cancer Institute of Canada 1986-1988 Member, Task Force on Strategic Planning, National Cancer Institute of Canada 1986-1988 Chair, Advisory Committee on Research, National Cancer Institute of Canada 1987-1990 Member, Scientific Review Panel, Israel Cancer Research Fund 1988-1989 Member, MRC Working Group on Guidelines for Somatic Cell Gene Therapy for

Disease 1988-1995 Member, Committee on Priorities & Planning, National Cancer Institute of Canada 1989-1995 Member, Scientific Board, Foundation Viamarconidieci, Italy 1989-1994 Member, International Scientific Council, Israel Cancer Research Fund 1989-1997 Member, Board of Directors, National Cancer Institute of Canada 1990 Member, Science Board, Biomedical Research Centre, Vancouver 1990 Member, Inter-Council Human Genome Advisory Committee 1990 Member-at-Large, National Cancer Institute of Canada 1991 Chair, Science Board, Biomedical Research Centre, Vancouver 1992-1995 Member, Medical Advisory Board, Thalassemia Research Foundation of Ontario 1992-1996 Member, Management & Executive Committees, Canadian Human Genome Project 1993 Member, Medical Research Council of Canada, Advisory Committee for Policy,

Planning, Analysis and Evaluation 1993 Member, National Cancer Institute of Canada Task Force on International Affairs 1993 Member, Conjoint Review Committee, Faculty of Medicine, University of Western

4

Ontario 1993 Member, Molecular Medicine External Advisory Committee, Fred Hutchinson

Cancer Research Center 1994-2000 Chair, International Scientific Council, Israel Cancer Research Fund, New York 1994-1997 Member, Standing Committee on Science and Research, Medical Research Council

of Canada 1995-1998 Member, Scientific Advisory Board, Visible Genetics Inc., Toronto 1995-2000 Member, Board of Directors, Cancer Care Ontario, Toronto 1995-2000 Member, Research Advisory Committee, Cancer Care Ontario, Toronto 1996-2000 Member, Board of Scientific Counsellors, National Cancer Institute, National

Institutes of Health, USA 1996-1999 Member, Mayor's Economic Partnerships Council, City of Toronto 1996- Member, The Committee of Excellence, Weizmann Institute of Science, Toronto 1997-2004 Member, Alberta Cancer Board - Advisory Committee on Research, Edmonton 1997-2000 Chairman, SAG, Biocatalyst Yorkton Inc., Toronto 1997-1999 Member, Seneca College - Biological Research Technology Advisory Committee,

Toronto 1997-2000 Chair, Toronto Biotechnology Commercialization Centre Board 1998-1999 Member, Scientific Advisory Board, Fred Hutchinson Cancer Research Center,

Seattle, Washington 1998-2000 Member, Roswell Park Cancer Institute's Scientific Advisory Board, Buffalo 1998- Member, Research Advisory Board, Juvenile Diabetes Foundation International, New

York 1998-2000 Member, Ontario Science Centre Board of Trustees, Toronto 1998-1999 Member, Ontario Biotechnology Task Force, Ministry of Energy, Science &

Technology, Toronto 1998-2000 Member, Unified Research Strategy Working Group, The Change Foundation,

Toronto 1998-2000 Member, Board of Directors, The Gerry & Nancy Pencer Brain Trust, Toronto 1998 Member, Canadian Institutes of Health Research Task Force, Ottawa 1999-2000 Member, Scientific Advisory Board, Canji, Inc., San Diego 1999-2000 Member, Scientific Advisory Committee, Alberta Heritage Foundation for Medical

Research, Edmonton, Alberta 1999-2003 Member, Scientific Advisory Board, The Van Andel Institute for Cancer Research,

Grand Rapids, Michigan 1999-2000 Member, Advisory Board, Roswell Park Cancer Institute, Buffalo 1999-2000 Member, Board Development Committee, Cancer Care Ontario, Toronto 2002 Member, Management Advisory Board, Juvenile Diabetes Research Foundation,

New York 2003-2006 Member, Biomedical Sciences International Advisory Committee, Singapore 2005- Member, Management Board, Alberta Ingenuity Prion Research Initiative 2007 Chair, International Review Panel, National Health and Medical Research Council,

Australia 2007 Member, Review Panel, The Walter and Eliza Hall Institute, Melbourne, Australia 2007- Chair, Scientific Advisory Board, Diamantina Institute, Brisbane, Australia

5

2008- Chair, International Board of Review, Alberta Ingenuity Board, Canada 2008- Member, Center for HIV/AIDS Vaccine Immunology, Durham, NC 2008- Member, AIDS Research Advisory Committee, Bethesda, MD 2008- Member, External Advisory Committee, Vaccine and Infectious Disease Institute,

Fred Hutchinson Cancer Research Center, Seattle, WA 2008-2011 Member, International Scientific Advisory Council, The Walter and Eliza Hall

Institute of Medical Research 2008- Member, Scientific Advisory Working Group, Vaccine Research Center, NIAID,

NIH 2009- Member, Board of Directors, Institut de Recherche en Immunologie et Cancérologie,

Université de Montréal, Montréal, Qc. Canada 2009- Member, Rotman Institute International Advisory Committee, University of Western

Ontario, London, Ontario, Canada 2009- Co-Chair, Chinese AIDS Vaccine Initiative Scientific Advisory Board SCIENTIFIC REVIEW AND PRIZE COMMITTEES (SELECTION): 1978 Scientific Officer, Grants Panel A, National Cancer Institute of Canada 1978-1982 Member, Grants Panel A, National Cancer Institute of Canada 1983 Member, Fellowship Panel, National Cancer Institute of Canada 1984 Member, Grants Panel on Cancer, Medical Research Council of Canada 1984-1985 Member, Special Study Section on Application of Recombinant DNA Technology to

Diagnosis of Cancer, National Cancer Institute, NIH 1985 Member, Special Reviewer, Mammalian Genetics Study Section, National Institutes

of Health, U.S.A. 1987 Chair, Sub-Committee on Developmental Biology, Gairdner Foundation International

Awards 1988 Chairman, Special Review Committee on "Genetics of Cell Lineages During

Mammalian Development," National Institute of Child Health and Human Development, NIH

1988-1989 Member, Clinical Sciences Study Section, Fellowship Committee, National Institutes of Health, U.S.A.

1993-1998 Member, Medical Review Panel, The Gairdner Foundation, Toronto 1999 Member, Review Panel for Biomedical Research Support Program for Medical

Schools of the Howard Hughes Medical Institute, Maryland 2000- Canadian Program in Genomics and Global Health (CPGGH) 1999-2001 Member, Charles S. Mott Medal Selection Committee, General Motors Cancer

Research Foundation, New York 2002- Member, Board of Directors, Canada’s Top 40 Under 40 2002 Chair, Charles S. Mott Selection Committee, General Motors Cancer Research Foundation, New York 2002-2007 Chair, The Canadian Medical Hall of Fame Selection Committee 2002- Member, Medical Advisory Board, The Gairdner Foundation, Toronto 2003-2004 Member, MRC (UK) Task Force on the National Institute for Medical Research

(NIMR) 2003-2006 Member, Assembly of General Motors Cancer Research Foundation, New York

6

2004- Member, Scientific Board, The Gates Foundation Grand Challenges in Global Health 2005 Member, Review Panel, The Walter and Eliza Hall Institute, Melbourne, Australia 2006 Member, Review Panel, UK National Health Service R&D Program in Translational

Biomedical Centres 2007- Chair, The Wolf Prize Jury, Medicine Prize, Israel UNIVERSITY COMMITTEES: 1977-1980 Elected Representative to the Council of the Faculty of Medicine, University of

Toronto 1980-1982 Graduate Secretary, Department of Medical Biophysics, University of Toronto 1981 Member, Search Committee for the Chairman of the Department of Medical

Biophysics, University of Toronto 1986-1987 Member, Search Committee for the Chairman of the Department of Medical

Biophysics, University of Toronto 1988-1989 Member, Search Committee for the Chairman of the Department of Microbiology,

University of Toronto 1989-1990 Member, The Dean's Advisory Committee to the Basic Sciences, Faculty of

Medicine, University of Toronto 1990 Member, Search Committee for the Director, Eye Research Institute of Ontario 1992-1993 Member, Research Committee, Department of Medicine, University of Toronto 1992-1993 Member, Search Committee for Chair, Department of Anatomy, University of

Toronto 1990-1998 Member, Promotions Committee, Department of Molecular and Medical Genetics,

University of Toronto 1991-1996 Member, Executive Committee, Interdepartmental Division of Oncology, University

of Toronto 1994-1997 Member, Faculty Research Committee, Department of Medicine, University of

Toronto 1994-2000 Member, Hospital/University Research Co-ordinating Committee, University of

Toronto 2006 Member, Executive Committee, Joint Centre for Bioethics, University of Toronto 2007 Member, Forum on Evidence-Based Health Policy Making, Nigerian Academy of

Sciences MOUNT SINAI HOSPITAL/FOUNDATION COMMITTEES: 1994-2000 Member, Medical Advisory Council, MSH 1994-2000 Member, Resource Development Council, MSHF 1994-2000 Member, Board of Directors, MSHF 1994-2000 Member, Board of Directors, MSH 1994-1996 Member, Joint Conference Committee, MSH 1995-2000 Member, Policy & Planning Advisory Group, MSH 1995-2000 Member, Executive Management Committee, MSH 1996-1998 Member, Corporate Strategy Planning Group, MSH

7

SAMUEL LUNENFELD RESEARCH INSTITUTE COMMITTEES: 1985-1994 Member, Research Advisory Committee 1989 Chairman, Committee - Long Term Planning 1992 Chair, 10th Floor Planning Committee 1992 Chair, Steering Committee 1992-1999 Member, Research Board 1994-2000 Chair, Research Advisory Committee 1994-2000 Chair, Executive Committee 1996-2000 Member, Executive Committee of the Research Board 1998 Chair, Search Committee, Head - Division of Epidemiology and Biostatistics EDITORIAL BOARDS: 1982-1993 Member, Editorial Board, Molecular and Cellular Biology 1989-1992 Member, Editorial Board, Technique 1989-2000 Member, Editorial Board, Environmental Management and Health; An International

Journal 1991-1995 Member, Editorial Board, Cell Growth & Differentiation 1992-1998 Member, Editorial Board, Blood 1995-1997 Member, Editorial Board, Mammalian Genome 1995-1997 Member, Editorial Board, Biology of Blood & Marrow Transplantation 1995-2000 Member, Board of Reviewing Editors, Science ORGANIZING COMMITTEES: 1976 Organizer, (with A.A. Axelrad and L. Siminovitch), National Cancer Institute of

Canada Workshop on Genetics and Cancer 1980-1981 Member, Organizing Committee for International Symposium on "Cellular and

Molecular Biology of Hemopoietic Stem Cells," Honey Harbour 1982-1983 Member, Organizing Committee for International Symposium on "Cellular and

Molecular Biology of Neoplasia," Honey Harbour 1986-1987 Member, Organizing Committee, "Biology of Growth Factors: Molecular Biology,

Oncogenes, Signal Transduction and Clinical Implications, Toronto, Canada, June 1987

1987-1988 Member, Program Committee, International Congress of Genetics, Toronto, Canada, August 1988

1988-1989 Member, Organizing Committee, East-Canadian Conference on Development and Cancer, Quebec City, June 1989

1988-1990 Member, Program Committee, UCLA Symposium on Manipulating the Mammalian Genome, Jackson Hole, Wyoming, January 1990

1993 Member, Organizing Committee, Symposium in Honour of Peter G. Scholefield, "New Directions in Cancer Research," Honey Harbour, Ontario, September 19-22, 1993

1993-1994 Member, Organizing Committee, 7th International p53 Workshop, Ontario, June 1994

1995 Member, Co-Organizer, Hematopoiesis, Howard Hughes Medical Institute, December 1995

8

1996 Member, Organizing Committee, Oncogene Meeting, Frederick, Maryland, June 1996

1998 Member, Organizing Committee, HGM2000, Vancouver, B.C., April 2000 Graduate Students: 1974-1980 Marcy E. MacDonald, Ph.D. 1975-1980 Dixie L. Mager, Ph.D. 1979-1983 Alex L. Joyner, Ph.D. 1981-1989 Ian Robson, Ph.D. 1982-1987 Stuart Berger, Ph.D. 1985-1990 James Ellis, Ph.D. 1987-1989 John Irish, M.Sc. 1985-1992 Alain Lavigueur, Ph.D. 1990-1993 Derek Rossi, M.Sc. 1990-1995 Liqun Zhang, Ph.D. 1991-1996 Xian-Hua Piao, Ph.D. 1990-1997 Michael Klüppel, Ph.D. 1993-1998 Mehran Sam, Ph.D. 1994-1999 Mira Puri, Ph.D. 1996-1998 Johanna Shulman, M.Sc. 1998-2004 Roddie Reventar, M.Sc. 2000- Jason Cohn, M.Sc. Postdoctoral Fellows: 1978 Dorothy McCool, Ph.D. (Toronto) 1979-1981 Yusei Yamamoto, M.D. 1981-1984 Michael Mowat, Ph.D. (Alberta) 1982 Jonathan Duke-Cohan, Ph.D. (London) 1983-1986 Dennis Huszar, Ph.D. (McMaster) 1984-1986 Virginia Chow, Ph.D. (Toronto) 1984-1986 John Dick, Ph.D. (Manitoba) 1985-1989 Sui-Pok Yee, Ph.D. (McMaster) 1986-1988 Benoit Chabot, Ph.D. (Yale) 1987-1989 Carol Steeg, Ph.D. (Cornell University) 1988-1990 Patrice Dubreuil, Ph.D. (Marseille) 1987-1991 Yaacov Ben-David, Ph.D. (Hebrew University) 1988-1991 Alastair Reith, Ph.D. (London University) 1989-1991 Norm Lassam, M.D. (McMaster) 1988-1991 Robert Rottapel, M.D. (George Washington University) 1991-1993 Richard Blouin, Ph.D. (Laval University) 1989-1993 Lesley Forrester, Ph.D. (University of Edinburgh) 1990-1993 Benny Motro, Ph.D. (Hebrew University) 1991-1993 Ken Kao, Ph.D. (Toronto) 1990-1994 Mary Brunkow, Ph.D. (Princeton) 1992-1995 Jonathan Lee, Ph.D. (Toronto)

9

1992-1995 John Abrahamson, M.D. (University of Ottawa) 1992-1996 Fabrice Melet, Ph.D. (University of Lyon) 1994-1996 Jacques Bollekens, M.D., Ph.D. (Belgium, Yale) 1992-1997 Klaus-Dieter Fischer, Ph.D. (University of Hamburg) 1994-1997 Mark Potter, Ph.D. (Oak Ridge) 1994-1997 Michihiro Hidaka, M.D., Ph.D. (Kumamoto Univ. Sch. of Med., Japan) 1993-1997 Pamela Correll, Ph.D. (George Washington University) 1993-1998 Robert Paulson, Ph.D. (UCSF) 1993-2000 Dorit Donoviel, Ph.D. (University of Washington) 1996-2000 Adam Hart, Ph.D. (Monash University, Melbourne, Australia) 1996-2000 Georgina Caruana, Ph.D. (University of Adelaide, Adelaide, South Australia) 1999-2000 Masa Hirashima, Ph.D. (Kyoto University, Japan) 1996-2000 Bill Stanford, Ph.D. (University of North Carolina, Chapel Hill, N.C.) 1998-2005 Yuki Kimura, Ph.D. (Nagoya University School of Medicine, Japan) 1999-2003 Mira Puri, Ph.D. (University of Toronto) 2001-2005 Kazunobu Tachibana, Ph.D. (Osaka University) Selected Invited Lectures: Interaction of inducers and inhibitors of Friend cell differentiation with the cell surface. Lady Davis

Institute. Montreal, Quebec, March 1976. Interaction of inducers and inhibitors of Friend cell differentiation with the cell surface. San

Francisco Medical Center, Cancer Research Institute. San Francisco, California. March 1976. Induction of erythroid differentiation in Friend cells; the role of the cell membrane. McMaster

University. Hamilton, Ontario, June 1976. Genetic approaches to erythroid differentiation in tissue culture. University of Western Ontario.

London, Ontario, December 1976. Role of cell surface in Friend cell differentiation. Institut du Cancer de Montreal. Montreal, Quebec,

January 1977. Approaches to the problem of gene expression in Friend hemopoietic cells. Roswell Park Memorial

Institute, Buffalo, New York, March 1977. Membrane event preceding and accompanying the induction of hemoglobin synthesis in Friend cells.

Max Planck Institute. Gottingen, West Germany, April 1977. Biochemical events culminating in the induction of erythroid differentiation in Friend cells. Imperial

Cancer Research Fund Laboratories. London, England, April 1977. Cellular and viral studies in erythropoiesis. Frederick Cancer Research Center. Frederick, Maryland,

April 1977. The program of Friend cell differentiation. Albert Einstein College of Medicine of Yeshiva

University. Bronx, New York, May 1978. Modulation of hemopoiesis by genetic determinants on RNA tumour viruses. Department of Medical

Research, Banting and Best Institute. Toronto, Ontario, April 1980. The role of host and viral genes in mouse leukemia. Department of Microbiology and Parasitology,

University of Toronto. Toronto, Ontario, April 1980. Modulation and transformation of hemopoietic progenitor cells by genetic determinants on RNA

tumour viruses. British Columbia Cancer Research Centre. Vancouver, B.C., May 1980. An infectious recombinant clone of Friend spleen focus forming virus DNA. Roswell Park

10

Memorial Institute. Buffalo, New York, October 1980. Malignant transformation of hemopoietic progenitor cells by a molecular clone of integrated Friend

spleen focus-forming virus DNA. University Hospital. London, Ontario, December 1980. Molecular and cellular biology of retrovirus induced leukemia in mice. Department of Biology,

University of Ottawa. Ottawa, Ontario, December 1981. Origin and properties of leukemic cell lines induced by molecular clones of Friend leukemia virus.

Department of Biology, York University. Toronto, Ontario, February 1982. Retrovirus induced leukemia. Department of Microbiology and Public Health, Michigan State

University. East Lansing, Michigan, March 1982. Erythroleukemia induction by a murine retrovirus. Department of Microbiology and Immunology,

University of Puerto Rio. San Juan, Puerto Rico, April 1982. Insertion of genes into retroviruses and retroviruses into genes. Department of Biology, McMaster

University. Hamilton, Ontario, December 1982. Molecular and cellular biology of Friend erythroleukemia. Harvard Medical School, Sidney Farber

Cancer Institute. Boston, Massachusetts, January 1983. Gene transfer into hematopoietic cells with naturally occurring and in vitro constructed murine retrovirus vectors. Department of Biochemistry, University of Calgary. Calgary, Alberta, March 1983. Gene transfer with retrovirus vectors. Imperial Cancer Research Fund Laboratories. London, U.K.,

September 1983. High frequency transfer of new genes into rodent and human cells with retrovirus vectors.

Distinguished lecturer. Hospital for Sick Children. Toronto, Ontario, December 1983. Gene transfer with retrovirus vectors. Baylor College of Medicine, Texas Medical Center. Houston,

Texas, April 1984. Gene transfer with retrovirus vectors. Immunobiology Research Center, University of Minnesota.

Minneapolis, April 1984. Gene transfer with retrovirus vectors. Department of Pathology, McMaster University. Hamilton,

Ontario, September 1984. Genomic modification of hematopoietic cells by retrovirus infection. Department of Biochemistry,

McGill University. Montreal, November 1984. Introduction of new genes into hematopoietic stem cells with retrovirus vectors. Sloan-Kettering

Institute for Cancer Research. New York, New York, November 1984. Future directions in cancer research. National Campaign Conference of the Canadian Cancer

Society. Toronto, Ontario, October 1985. Transfer of new genes into hematopoietic stem cells. Department of Immunology, Hospital for Sick

Children. Toronto, Ontario, October 1985. Transfer of new genes into pluripotent and totipotent stem cells with retrovirus vectors. Lady Davis

Institute for Medical Research. Montreal, Quebec, November 1985. Transfer of new genes into pluripotent and totipotent stem cells with retrovirus vectors. Department

of Medical Research, Banting & Best Institute. Toronto, Ontario, November 1985. Gene transfer with transfer vectors. NCI-Frederick Cancer Research Facility. Frederick, Maryland,

January 1986. Gene transfer into pluripotent hematopoietic stem cells. Department of Pathology, New York

University. New York, New York, April 1986. Retrovirus vectors. Department of Microbiology, University of Rochester. Rochester, New York,

11

October 1986. Introduction of new genetic information into hematopoietic stem cells: implications for gene

therapy. Department of Microbiology, Hebrew University. Jerusalem, Israel, October 1986. Introduction of new genetic information into hematopoietic stem cells: implications for gene

therapy. The Weizmann Institute of Science. Rehovot, Israel, October 1986. Introduction of new genetic information into hematopoietic stem cells: implications for gene

therapy. Ben Gurion University. Beer Sheba, Israel, October 1986. Introduction of new genetic information into hematopoietic stem cells: implications for gene

therapy. Department of Microbiology, Tel Aviv University. Tel Aviv, Israel, November 1986. Gene transfer into mouse and human stem cells. Department of Biochemistry, Baylor College of Medicine. Houston, December 1986. Introduction of new genes into hematopoietic stem cells with retrovirus vectors. Department of

Biochemistry, Queen's University. Kingston, Ontario, February 1987. Human gene therapy: current status and future prospects. Grand Rounds, Kingston General

Hospital. Kingston, Ontario, February 1987. Introduction of new genetic information into hematopoietic stem cells: implications for gene

therapy. McGill University, Cell and Molecular Biology Seminar Series. Montreal, Quebec, April 1987.

Introduction of new genes into mouse hematopoietic stem cells with retrovirus vectors. McArdle Laboratory for Cancer Research, University of Wisconsin. Wisconsin, April 1987.

Analysis of early events in hematopoietic stem cell differentiation. Department of Molecular Biology and Biochemistry, Northwestern University. Chicago, Illinois, April 1987.

Introduction of new genes into hematopoietic stem cells: implications for gene therapy. Center for Genetics, University of Illinois College of Medicine. Chicago, Illinois, May 1987. Memorial University. St. John's, Newfoundland, July 1987.

Gene transfer with retrovirus vectors. Laval University, Cancer Research Centre. Quebec, December 1987. Dupont Experimental Station. Wilmington, Delaware, December 1987.

Amplification and ablation of specific cell types in transgenic mice. Department of Cell Biology, Albert Einstein College of Medicine. April 1988.

The p53 oncogene: a positive or negative regulator of cell growth? Molecular Biology Program, Memorial Sloan-Kettering Cancer Center. New York, New York, January 1989.

Analyzing the role of oncogenes in development and malignancy using transgenic and mutant mice. Third Annual Health Sciences Centre Scientific Day, Memorial University of Newfoundland. St. John's, Newfoundland, March 1989.

The mouse W/c-kit locus: a mammalian proto-oncogene that controls melanogenesis, hematopoiesis and gametogenesis. Imperial Cancer Research Fund Laboratories. London, U.K., April 1989.

The c-kit and p53 oncogenes: analysis in mutant and transgenic mice. The Institute of Cancer Research, Royal Cancer Hospital. London, U.K., April 1989.

The mouse W locus: germ-line mutants in a mammalian proto-oncogene. Sir William Dunn School of Pathology, Oxford University. Oxford, U.K., May 1989.

The c-kit and p53 oncogenes: positive and negative regulators of cell growth. Department of Microbiology, University of Toronto. Toronto, Ontario, May 1989.

The p53 and c-kit oncogenes in normal, transgenic and genetically anemic mice. The Wistar Institute. Philadelphia, Pennsylvania, September 1989.

Dominant-negative mutations in the p53 and c-kit oncogene in transgenic and mutant mice.

12

Department of Biology, Princeton University. Princeton, New Jersey, September 1989. The p53 and c-kit oncogenes in W mutant and transgenic mice. Lineberger Cancer Research Center,

The University of North Carolina at Chapel Hill. North Carolina, November 1989. Dominant negative mutations in the p53 and c-kit oncogenes in transgenic and mutant mice.

Massachusetts General Hospital Cancer Center, Harvard Medical School. Charlestown, Massachusetts, December 1989.

Dominant negative mutation in the c-kit and p53 oncogenes in transgenic and mutant mice. State University of New York Health Science Center at Brooklyn. Brooklyn, New York, March 1990.

The mouse W/c-kit locus: A cellular proto-oncogene that controls hematopoiesis, gametogenesis and melanogenesis. Department of Human Genetics, Yale University. New Haven, Connecticut, May 1990.

The mouse W/c-kit locus. International Institute for Genetics and Biophysics. Naples, Italy, May 1990.

Molecular analysis of the W/c-kit locus: A mammalian proto-oncogene that controls hematopoiesis, melanogenesis and gametogenesis. Pasteur Institute. Paris, France, May 1990.

Identification and analysis of genes that control normal and leukemic hematopoiesis. National Institute for Medical Research. Mill Hill, England, July 1990.

Developmental consequences of germ-line mutations in the c-kit proto-oncogene. Imperial Cancer Research Fund. London, U.K., July 1990.

Biological and molecular analysis of mutations in the mouse that control receptor tyrosine kinase cell-signalling pathways. McGill Cancer Center. Montreal, Quebec, October 1990. Identification and analysis of mutations that control normal and leukemic hematopoiesis.

Department of Biochemistry, University of Western Ontario. London, Ontario, November 1990. Developmental consequences of germ-line mutations in a cell signalling pathway. Aser Rothstein

Lecture, Hospital for Sick Children Annual Institute Retreat. Toronto, Ontario, December 1990. The W/Steel signal transduction pathway: Its role in embryogenesis and hematopoiesis. VA Medical

Center. Charleston, South Carolina, May 1991. Developmental genetics of cell signalling during mammalian development: The W/Sl Signal

Transduction Pathway. National Institute of Health. Bethesda, Maryland, May 8, 1991. Eastern Canadian conference on development and cancer. Montreal, Quebec, September 23-25,

1991. Identification and analysis of genes that control hematopoiesis. Johns Hopkins Oncology Center.

Baltimore, Maryland, January 28, 1992. The hematopoietic system and diseases. Montreal Cancer Institute. Montreal, Quebec, April 24,

1992. Molecular analyses of germ-line mutations that affect melanogenesis in mice and man. Johnson &

Johnson Skin Biology Research Center. New Brunswick, New Jersey, April 28-29, 1992. Molecular analysis of the multistage erythroleukemias induced by the Friend viruses. Institut Curie.

Paris, France. August 20, 1992. From erythropoietin to Steel factor: Insights into the molecular regulation of the hematopoietic stem

cell hierarchy. Allan J. Erslev Distinguished Lectureship. Philadelphia, PA. November 13, 1992. Louis J. Cole Lecture in Gastroenterology. Mount Sinai Hospital. Toronto, Ontario, November 20,

1992. McMaster University, Department of Biochemistry Seminar. Hamilton, Ontario. November 24,

1992.

13

Max-Planck Institute of Immunobiology Lecture. Freiburg, Germany. January 13, 1993. Proto-oncogenes, tumour suppressor genes and the control of hematopoiesis. Howard Hughes

Medical Institute, Washington University School of Medicine. St. Louis, Missouri. February 12, 1993.

Oncogenes, tumour suppressor genes and the control of hematopoiesis. Memorial Sloan-Kettering. New York, New York. March 24, 1993.

From white mice to Steel factor: Better living through genetics. The Terry Fox Laboratory for Hematology/Oncology, Distinguished Speaker Seminar Series. Vancouver, BC. December 2, 1993.

Department of Microbiology and Molecular Genetics, New Jersey Medical School. Newark, New Jersey. March 22, 1994.

Oncogenes, tumour suppressor genes and the control of hematopoiesis. Lady Davis Institute for Medical Research. Montreal, Quebec. April 15, 1994.

Oncogenes, tumour suppressor genes and the control of hematopoiesis. Department of Genetics, College of Medicine, The University of Illinois at Chicago. Chicago, Illinios. April 13, 1994.

The Kit receptor tyrosine kinase: multiple functions in multiple cell types. Developmental Lung Biology Research Rounds, Hospital for Sick Children, Toronto, January 16, 1995.

Genetic approaches to mast cell development and sigalling. Workshop on Signal Transduction in the Activation and Development of Mast Cells and Basophils. Bethesda, Maryland.

February 20-23, 1995. Mouse mutants carrying gain or loss of function mutations in the Fli transcription factor gene.

Workshop on Nuclear Oncogenes and Transcription Factors in Hematopoietic Cells. Madrid, Spain. April 24-26, 1995.

W/Kit and Sl loci and their multiple roles in mouse development. Distinguished Lecturer, Oak Ridge National Laboratory, Tennessee. May 16-17, 1995.

Ninth International Biotechnology Meeting & Exhibition. Luncheon Speaker. San Francisco, CA. May 20-25, 1995.

The W/c-Kit receptor and its multiple roles in development and malignancy. Guest Speaker - DNAX Colloquium Lecture Series. Palo Alto, California. September 14, 1995.

Biotechnology and its impact on society. Biotechnology Week: Biotech Alive! Ontario Science Centre, Toronto, Ontario. May 11, 1996.

Genetic engineering - how far do we go? A Jewish Response to Biomedical Ethical Concerns, Temple Sinai, Toronto, Ontario. April 6, 1997.

Explosion of Discovery in Cancer Research. North Bay & District Unit, Canadian Cancer Society, North Bay, Ontario. April 4, 1997.

Receptor tyrosine kinases and the control of development, hematopoiesis, and the inflammatory response. City-Wide Nephrology Rounds (University of Toronto), Hospital for Sick Children, Toronto, Ontario. April 9, 1997.

Genes _R_ Us. Biotechnology Week: Biotech Alive! Ontario Science Centre, Toronto, Ontario. May 6, 1997.

The Future of Biotechnology (Keynote Speaker). Biotechnology Day, Michener Institute, Toronto, Ontario. May 30, 1997.

An Update: State of the Art Cancer Research in Israel (Keynote Speaker). Israel Cancer Research Fund Annual Meeting, Montreal, Quebec. October 9, 1997.

Molecular Genetics of Hematopoiesis and Vasculogenesis. Roswell Park Cancer Institute, Buffalo,

14

New York. May 13, 1998. The Molecular Genetics of Hematopoiesis and Vasculogenesis -The 2nd Annual Rose Winner

Lecture in Human Cancer Genetics. Dana-Farber Cancer Institute, Boston, Mass. May 19, 1998. Biomedical Research in the Post-Genomics Era. Business Issues for Bioscience Companies

Conference, London, England. October 5-6, 1998. Biomedical Research in the Post-Genomics Era (Keynote Speaker). Pharmaceutical Manufacturers

Association of Canada Annual General Meeting, Toronto, Ontario. November 3, 1998. Genetic and Genomic Approaches to Hematopoiesis and Vascular Development (Keynote Speaker).

1998 Alberta Cancer Board's Annual Research Meeting, Calgary, Alberta. November 9, 1998. Genetic and Genomic Approaches to Hematopoiesis and Vascular Development, Honors Program

Lectures 1998-99, New York University Medical Center, New York, NY. January 25, 1999. Genetic and Genomic Approaches to Hematopoiesis and Vasculogenesis. The Pennsylvania State

University, University Park, Pennsylvania. April 26-27, 1999. The Genetics Revolution and its Impact on our Health Care System. Rotman School of

Management, University of Toronto, Toronto, Ontario. June 24, 1999. Genetics and genomics of heamtopoiesis and vasculogenesis. Clinical Research Institute of

Montreal. December 1, 1999. Genetic and genomic approaches to hematopoiesis and vasculogenesis. Distinguished Scientific

Leadership Lecture - BC Cancer Agency/Vancouver Hospital. February 15, 2000. AMS/ACAHO John Neilson Memorial Speaker, Club Tremblant, Mont-Tremblant,

Quebec, September 15, 2000. Genetics and Genomic Approaches to Vascular Development and Hematopoiesis. UBC McDonald

Research Laboratories/iCAPTUR4E Centre inaugural Distinguished Lectureship for 2002. Vancouver, December, 2002

Invited Symposia Presentations (Selection): Molecular and cellular events leading to the induction of erythroid differentiation in Friend

erythroleukemic cells. Cold Spring Harbor Meeting on Differentiation of Normal and Neoplastic Hematopoietic Cells. Cold Spring Harbor, New York, September 1977.

The program of Friend cell erythrocyte differentiation. Canadian Biochemical Society, Symposium on Cell Differentiation. London, Ontario, June 1978.

RNA tumour viruses: cloning vectors for cellular genes involved in malignant transformation. Symposium on Mechanisms of Pathogenicity, McMaster University. Hamilton, Ontario, November 1980.

Malignant stem cell clones in Friend leukemia. The Gordon Conference on the Red Cell. Plymouth, New Hampshire, June 1981.

Erythroid differentiation and Friend leukemia virus. First Annual Queen's University Symposium on Gene Expression. Kingston, Ontario, August 1981.

Molecular and cellular biology of Friend leukemia. INSERM Conference on Viral Genes and Leukemogenesis: Molecular, Cellular and Physiological Approaches. Paris, France October 1981.

Erythroid cell development and erythroleukemia. Conference on Tumor Virus and Differentiation. 1982 UCLA Symposia on Molecular & Cellular Biology. Squaw Valley, California, March 1982.

Gene transfer using retrovirus vectors. Workshop on Gene Transfer and Cancer, NCI-Frederick Cancer Research Facility. Frederick, Maryland, April 1982.

Generation of retrovirus vectors by in vitro and in vivo recombination. Carolina Conference - Gene

15

Transfer and Gene Expression. Raleigh, North Carolina, November 1982. Gene transfer via retrovirus vectors. Canadian Federation of Biological Sciences Symposium on

Molecular Genetics of Cancer. Ottawa, Ontario, June 1983. Retrovirus transduction. First Terry Fox Cancer Research Conference on Oncogenes and Cancer.

Vancouver, British Columbia, July 1983. Gene transfer into hematopoietic stem cells. Jackson Lab Meeting on Stem Cells. Bar Harbor,

Maine, July 1983. Retrovirus transduction. First Terry Fox Cancer Research Conference on Oncogenes and Cancer.

Vancouver, British Columbia, July 1983. Gene transfer using retrovirus vectors. 13th Annual Queen's University Symposium on Gene

Transfer and Expression. Kingston, Ontario, August 1983. Gene transfer in vitro and in vivo with Friend and Moloney Retrovirus vectors. EMBO Workshop

on Haemopoiesis and Leukaemogenesis. Aviemore, Scotland, September 1983. Update on oncogenes. Southern Ontario Carcinogenesis Group, McMaster University. Hamilton,

Ontario, November 1983. Gene transfer with retrovirus vectors. Canadian Federation of Biological Sciences. Toronto, Ontario,

June 1985. Cellular and molecular events associated with multi-stage murine erythroleukemia. FASEB Summer

Research Conference on Mechanisms of Carcinogenesis. Vermont, New Hampshire, July 1985. Transfer of genes into stem cells. The Genetics of Development. Honey Harbour, Ontario,

September 1985. Vectors for gene transfer in animals. Western Winter UCLA Symposium. Lake Tahoe, California,

February 1986. Stem cell transfections. Reticuloendothelial Society International Workshop, Molecular Biology

and Genetic Approaches in Leukocyte Biology. Kiawah Island, South Carolina, March 1986. Gene transfer into hematopoietic stem cells: Implications for gene therapy. Cold Spring Harbor

Symposium on Molecular Biology of Homo Sapiens. Cold Spring Harbor, NY, May 1986. Gene transfer with retrovirus vectors. International Symposium on Normal and Neoplastic Blood

Cells: From Genes to Therapy. Rome, Italy, June 1986. Retrovirus-mediated modulation of hematopoietic cells and opportunities for gene therapy. Gordon

Conference on Cancer. Vermont, August 1986. Transfer of new genetic information into mouse and human hematopoietic stem cells. 7t International

Congress of Human Genetics. West Berlin, Germany, September 1986. Gene transfer in hematopoietic cells in mice. 3rd International Symposium on Autologous Bone

Marrow Transplantation. Houston, Texas, December 1986. Gene transfer into hematopoietic stem cells with retroviral vectors. Symposium on hematopoietic

growth factors. American Society for Hematology. San Francisco, California, December 1986. Introduction of new genes into hematopoietic stem cells. Chair, ICN-UCLA Symposium on Recent

Advances in Leukemia and Lymphoma. Keystone, Colorado, January 1987. Growth factors, differentiation and oncogenesis. The Canadian Society for Immunology, Spring

Meeting. Chateau Lake Louise, Alberta, March 6-9, 1987. Viruses as genetic vectors. 7th International Congress of Virology, Co-chairman, Round Table

Discussion. Edmonton, Alberta, August 1987. Gene transfer into hematopoietic cells. Gordon Conference on the Red Cell, "Transfer of Genes into

Marrow Stem Cells." Plymouth, New Hampshire, August 17-21, 1987.

16

Conference on Stem Cells and Autologous Bone Marrow Transplantation. Vancouver, British Columbia, September 21-22, 1987.

High efficiency gene transfer with retrovirus vectors. Advances in Recombinant DNA Technology: The Lake Tahoe Symposium. Lake Tahoe, Nevada, September 28-30, 1987.

First Canadian AIDS Research Conference. Chairman for Molecular Biology Session. Toronto, Ontario, January 27-29, 1988.

Programmed amplification and ablation of specific cell lineages in transgenic mice. UCLA Symposium on Molecular and Cellular Biology: Gene Transfer in Animals. Tamarron, Colorado, February 6-12, 1988.

Ablation and amplification of specific cell types in transgenic mice. First Israeli Conference on Cancer Research. Tiberias, Israel, March 10-12, 1988.

Amplification and ablation of specific cell types in transgenic mice. Banff N.W. Molecular Biology Conference. Banff, Alberta, April 26-29, 1988.

The molecular biology of development: retrovirus vectors and transgenic mice. Opening Symposium, The Biomedical Research Centre, University of British Columbia. Vancouver, British Columbia, May 5, 1988.

Human gene therapy: prospects and public policy issues. Canadian Association for Biological Safety: Testing and Applications of Bioengineered Organisms in the Environment. Calgary, Alberta, June 1-3, 1988.

Modification of hematopoietic cells by gene transfer into the germ line and somatic cells. American Society of Hematology Spring Symposium. Seattle, Washington, June 6-7, 1988.

Gene transfer into haemopoietic cells. Workshop on Hematopoietic Growth and Differentiation Factors. Melbourne, Australia, August 6-9, 1988.

Gene transfer and gene targetting with retroviral vectors. Workshop on Retrovirally Mediated Gene Transfer. Sydney, Australia, August 10-12, 1988.

Chair, Prospects for gene therapy. XVI International Congress of Genetics. Toronto, Ontario, August 20-27, 1988.

Analysis of hematopoietic stem cell function using transgenic and mutant mice. Sixth Conference on Hemoglobin Switching. Airlie House, Virginia, September 25-28, 1988.

Molecular analysis of normal and leukemic hematopoiesis using retrovirus vectors and transgenic mice. Viral Oncogenesis and Cell Differentiation: The Contributions of Charlotte Friend. New York, New York, September 29-October 1, 1988.

The murine W locus: a germ-line mutation in a mammalian proto-oncogene. UCLA Symposium on Biotechnology and Human Genetic Predisposition to Disease. Steamboat Springs, Colorado, April 1989.

P53: A positive or negative regulator of cell growth? NCI Workshop on T-Antigens and Proto-oncogene Interactions. Gaithersburg, Maryland, April 1989.

Cellular proto-oncogenes and the control of haemopoiesis. CIBA Foundation Symposium on Molecular Control of Haemopoiesis. London, U.K., May 1989.

Molecular analysis of cell lineages with naturally occurring and transgenic mouse mutants. Howard H. Holzer Symposium on Developmental Biology. Philadelphia, Pennsylvania, May 1989.

W/c-kit locus control of cell lineages. East-Canadian Conference on Development and Cancer. Quebec City, Quebec, May 1989.

W: A germ-line proto-oncogene mutation affecting pigmentation, fertility and erythropoiesis. 60th Anniversary Symposium in Honor of Dr. Elizabeth Russell. Bar Harbor, Maine, June 1989.

17

The mouse W/c-kit locus. Gordon Conference on Developmental Biology. Plymouth, New Hampshire, July 1989.

The mouse W/c-kit locus. Gordon Conference on the Red Cell. Plymouth, New Hampshire, August 1989.

Introduction of specific point mutations into RNA PolII by gene targetting in mouse ES cells. NIH Workshop on Applications of Homologous Recombination to Human Disease. Bethesda, Maryland, November 1989.

The mouse W/c-kit locus: Pleitropic developmental defects as the result of dominant-negative amino acid substitutions in a membrane receptor tyrosine kinase. UCLA Symposium: Manipulating the Mammalian Genome. Tamarron, Colorado, January 1990.

Germ-line mutations in the c-kit growth factor receptor: Their effects on growth and development in W mutant mice. UCLA Symposium: Growth and Differentiation Factors in Embryonic Development. Steamboat Springs, Colorado, March 1990.

INSERM Workshop on Homologous Recombination and In Vivo Targeted Mutagenesis. 1. Gene targeting with retroviral vectors. 2. Introduction of specific point mutations into RNA polymerase II by gene targeting in mouse ES cells. Paris, France, May 1990.

Dominant-negative mutations in the murine W/c-kit and p53 genes: Their effects on development and cancer. 3rd International Conference on Genetic Transfer and Alteration in Biology and Medicine. Vienna, Austria, May 1990.

Identification and analysis of genes that control normal and leukemic hematopoiesis. 9th Wilsede Meeting on Modern Trends in Human Leukemia. Wilsede, Federal Republic of Germany, June 1990.

Molecular analysis of the mouse W/c-kit locus: A mammalian proto-oncogene that controls hematopoiesis, gametogenesis, and melanogenesis. Genetics Society of America/Genetics Society of Canada Joint Meeting. San Francisco, California, July 1990.

Dominant-negative mutations in cellular oncogenes in mutant and transgenic mice: Their effect on development and neoplasia. The International Society for Differentiation, Sixth International Conference on Differentiation of Normal and Neoplastic Cells. Vancouver B.C., July 1990.

The W/c-kit locus. 19th Annual Meeting of the International Society for Experimental Hematology. Seattle, Washington, August 1990.

Developmental consequences of germ-line mutations in the mouse W/c-kit receptor tyrosine kinase. European Molecular Biology Organization Symposium on the Molecular Biology of Vertebrate Development. Heidelberg, Germany, September 1990.

Presidential Symposium: The W, steel and mi gene loci and the control of hematopoiesis. International Society of Hematology - 23rd Congress and American Society of Hematology - 32nd Annual Meeting. Boston, Massachusetts, December 1990.

Molecular and biological analysis of mouse mutations controlling hematopoietic stem cells. Keystone Symposium on Leukemia: Advances in Biology and Therapy - Progress and Controversies. Big Sky, Montana, April 1991.

Molecular and developmental analysis of germ-line mutations in the W/c-kit receptor. Keystone Symposia on Cytokines and Their Receptors: From Clonal to Clinical Investigation. Keystone, Colorado, April 1991.

Molecular analysis of developmental mutations at the W, Steel and Mi Loci. Workshop on the Biology of Stem Cells: Program in Molecular Medicine of the Fred Hutchinson Cancer Research Center, Seattle, Washington, April 1991.

18

Strategies for identification of genes controlling normal and leukemic hematopoiesis. Third Anniversary Symposium, Biomedical Research Centre. Vancouver, British Columbia, April 1991.

The W, steel and mi gene loci and the control of hematopoiesis. Symposium on Hematopoietic Growth Factors. University of California, Los Angeles. Los Angeles, California, June 1, 1991.

Molecular analysis of mutations that affect early events in embryogenesis and hematopoiesis. Pasteur-Weizmann Symposium. Rehovot, Israel, June 1991.

Molecular approaches to the control of hematopoiesis. 2nd International Symposium on Molecular Biology of Hematopoiesis. Innsbruck, Austria, July 14-18, 1991. Molecular approaches to stem cell function: The W/Sl signal transduction pathway. 20th Annual

Meeting of the International Society for Experimental Hematology. Parma, Italy, July 21-25, 1991.

Germ-line mutations in the murine c-kit and c-fms signalling pathways. Arolla Workshop 1991, From Receptor to Gene. Zurich, Switzerland, August 25-30, 1991.

The W/Sl signal transduction pathway. Second Annual Schweppes/Northwestern University Cancer Center Symposium on Molecular Development. Evanston, Illinois, October 1991.

15th Bristol-Myers Squibb Symposium on Cancer Research. Seattle, Washington, November 4-5, 1991.

Germ-line genetic approaches to understanding normal and leukemic hematopoiesis. Maimonides Conference on Cancer Research. Ein-Gedi, Israel, November 25-30, 1991.

Molecular and cellular aspects of the W/c-kit signal transduction pathway, Cell traffic in embryology and immunology. Table Ronde Roussel-Uclaf, Institute Scientific Roussel. Paris, France, December 5-6, 1991.

The c-kit signal transduction pathway and the control of hematopoiesis. Keystone Symposium on Molecular and Cellular Biology: Hematopoiesis. Tamarron, Colorado, February 27-March 5, 1992.

Molecular analyses of germ-line mutations that affect melanogenesis in mice and man. Johnson & Johnson Skin Care Scientific Advisory Board Pigmentation Workshop. New Brunswick, New Jersey. April 28-29, 1992.

From white mice to Steel factor: New insights into the regulation of hematopoiesis. Symposium on The Stem Cell and the Influence of its Microenvironment on Hematopoiesis. National Pediatric Blood Club/American Pediatric Society/Society for Pediatric Research. Baltimore, Maryland, May 6, 1992.

Molecular genetics of the dominant white-spotting (W) and Steel Loci. Keynote Address, PanAmerican Society for Pigment Cell Research, IVth Annual Meeting. Cincinnati, Ohio, June 7-10, 1992.

Oncogenesis in p53 transgenic mice. 5th International Congress of Cell Biology. Chair: Symposium on Transgenic Animals to Study Human Diseases. Madrid, Spain, July 26-31, 1992.

The doctor's dilemma: Molecular biology and the future of biomedical research. 19th Annual Meeting, The Society for the Study of Fetal Physiology. Niagara-on-the-Lake, Ontario, August 25, 1992.

The Kit signalling pathway and its role in hematopoiesis, gametogenesis and neurogenesis. 10th Whitehead Institute Symposium: Cell Interactions in Development and Disease. Cambridge, Massachusetts, October 4-6, 1992.

Molecular controls on normal and leukemic hematopoietic cells. The American Association for Cancer Research (AACR) Meeting on Normal and Neoplastic Growth and Development.

19

Chatham, Massachusetts, October 18-22, 1992. Molecular control of hematopoietic stem cell function. Princess Liliane Symposium on Blood Cells

and Leukemia. Brussels, Belgium, October 25-27, 1992. Normal and leukemic hematopoiesis in p53 transgenic mice. 6th p53 Workshop. Tiberias, Israel,

November 1-5, 1992. Molecular and cellular approaches to hematopoietic stem cell function. NIDDK Symposium on the

Impact of Molecular Genetics on the Treatment of Genetic Diseases. Washington, D.C., November 12, 1992.

Molecular genetics of cell signalling in the mouse. American Society for Cell Biology (ASCB) Symposium on Cell Signalling in Development. Denver, Colorado, November 15-19, 1992.

The W and Sl loci and the control of hematopoiesis. Society for Leukocyte Biology Meeting, Genetic Engineering Session. Charleston, South Carolina, December 2-5, 1992.

The c-kit receptor in normal, leukemic and mutant cells. National Heart, Lung and Blood Institute (NHLBI) Conference on Cytokines and Cytokine Receptors in Health and Disease. Bethesda, Maryland, December 2-3, 1992.

Genetic damage and escape from proliferation control. ISREC: Second Symposium on Cancer Research. Lausanne, Switzerland. January 14-15, 1993.

Bologna Symposium - Blood Cell Growth Factors: Their Role in Congenital Dysplasias. Bologna, Italy. March 8-9, 1993.

Second Annual Meeting on Signal Transduction in Normal and Cancer Cells. Banff, Alberta. April 1-5, 1993.

Second International Workshop on 'The Genetic Control of Vertebrate Development.' Kolymbari, Crete, Greece. May 1-7, 1993.

Workshop on Signal Transduction by Growth Factor Receptors with Tyrosine Kinase Activity. (Fundación Juan March). Madrid, Spain. May 10-12, 1993.

84th Annual Meeting of the American Association for Cancer Research (AACR). 'The biological and therapeutic application of normal and hematopoietic stem cells.' Orlando, Florida. May 19-22, 1993.

Canadian Federation of Biological Sciences: Growth & Differentiation. Windsor, Ontario. June 17-19, 1993.

International Association for Comparative Research on Leukemia & Related Diseases. Montreal, Quebec. July 11-16, 1993.

Mouse Molecular Genetics Meeting. Heidelberg, Germany. August 18-22, 1993. International Society for Experimental Hematology (ISEH), 22nd Annual Meeting. Rotterdam,

Netherlands. August 22-26, 1993. Third Mammalian Genetics Workshop. Bar Harbor, Maine. September 8-12, 1993. XV International Pigment Cell Conference. London, England. September 26-30, 1993. OCTRF 14th Biennial Cancer Research Conference: Preventive Oncology. Lake Couchiching,

Ontario. October 4-6, 1993. Molecular genetics of the Kit signal transduction pathway. Third International Mochida Memorial

Symposium: Horizon in Cytokine Research. Shinjuku, Tokyo, Japan. October 22-24, 1993. Biological and molecular consequences of signalling through the Kit pathway. FASEB Meeting:

Signal Transduction and the Regulation of Hematopoietic Cell Growth and Development. Anaheim, California. April 24-28, 1994.

Biological and molecular insights into the Kit/SCF pathway. Amgen Workshop: The Role of SCF

20

in Fertility and Embryogenesis. Santa Monica, California. July 6, 1994. The Fli -1 and Spi-1/PU.1 ets genes and their roles in malignancy and normal development. Gordon

Research Conference on Cancer. New London, New Hampshire. August 14-19, 1994. Insights into hematopoiesis from the analysis of mutant mice. 23rd Annual Meeting - International

Society for Experimental Hematology. Minneapolis, Minnesota. August 21-25, 1994. Phenotypic analysis of mice with dominant-negative mutations in the c-Kit proto-oncogene and the

p53 tumor suppressor gene. Symposium at Onyx Pharmaceuticals: Transgenic Animal Model Systems. Richmond, California. September 19, 1994.

Genetic approaches to the analysis of mammalian signal transduction pathways. Howard Hughes Medical Institute Scientific Meeting: The Experimental Analysis of Gene Function. Chevy Chase, Maryland. October 9-12, 1994.

The p53, PU.1/Spi-1 and Fli-1 transcription factors and their roles in development and neoplasia.

American Association for Cancer Research (AACR) Symposium, Toronto, Ontario. March 22, 1995.

Mouse models of p53 loss. Signal Transduction of Normal and Tumor Cells. American Association for Cancer Research (AACR) Symposium, Banff, Alberta. April 1-6, 1995.

Gene Therapy: The reality and the expectations. Symposium on Gene Therapy in Canada. Toronto, Ontario. June 26-27, 1995.

The W/Kit and Sl loci: The molecular genetics of a key signalling pathway in stem cell biology. CRC Beatson International Cancer Conference on Stem Cells in Development and Cancer. Glasgow, Scotland. August 20-23, 1995.

Meeting Summary. Stem cells: Where are we now? CRC Beatson International Cancer Conference on Stem Cells in Development & Cancer. Glasgow, Scotland. August 20-23, 1995.

Molecular genetics of the c-kit/S1 signalling pathway. Howard Hughes Medical Institute Scientific Workshop: Hematopoiesis. Chevy Chase, Maryland. December 10-13, 1995.

Germline and somatic mutations in the W/c-Kit receptor tyrosine kinase in development and malignancy. 1995 Annual Symposium on Molecular and Cellular Biology of Man. Osaka, Japan. February 19-21, 1996.

Germline and somatic mutations in the W/c-Kit receptor tyrosine kinase in development and malignancy. The 7th Lorne Cancer Conference. Lorne, Australia. February 19-21, 1996.

Gene targeting and gene trapping: functional genomics of the mouse. Research Workshop of the Israel Science Foundation, Rehovot, Israel. September 21-24, 1997.

From mutant mice to new therapies: Genetic approaches to drug discovery. Graduate Research in Progress Symposium, Organized by the Pharmacy Graduate Student Association, Graduate Department of Pharmaceutical Sciences, University of Toronto. Toronto Hilton Hotel, February 16, 1998.

Receptor tyrosine kinases and blood vessel development. Keystone Symposium on Molecular Biology of the Cardiovascular System, Steamboat Springs, Colorado, March 28-April 3, 1998.

Receptor tyrosine kinases in hematopoiesis and vasculogenesis. Keystone Symposium on Oncogene Networks in Signal Transduction, Keystone, Colorado. April 9-14, 1999.

Biomedical research and biomedicine in the 21st Century. Society of Toxicology of Canada - 32nd

Annual Symposium, Montreal, Quebec. December 2-3, 1999.

21

Non-Scientific Presentations: ‘Turning Research Into Action: CIHR’s Practive Role in Health Research and the Canadian Health Care System’. Keynote Address, AAPS Conference. Toronto, Ontario. November 10, 2002 CIHR’s Revolutions: Attracting the Best and Brightest. Keynote Address, Ontario Medical Student

Week, University of Toronto. November 22-24, 2002 Harvard meeting on Genomics, 2000/2001 Health Research in the 21st Century – The Great Adventure. University of Ottawa Resident’s Research Day. Ottawa, Ontario. May 23, 2002 CIHR and Global Health. Canadian Society of International Health Annual Conference and Workshop. Ottawa, Ontario. October 29, 2002 Health and Health Research: Canada’s Meeting Ground for Innovation. National Summit on Innovation and Learning. Vancouver, British Columbia. November 19, 2002 Canadian University Undergraduate Technology Conference. Toronto, Ontario. January 17, 2003 Putting the Geee! In Genome. Exhibit opening, Canadian Museum of Nature. Ottawa, Ontario. April 25, 2003. Community-University Research: Perspectives from a Funder. CUExpo2003. Saskatoon, Saskatchewan. May 9, 2003 Research and the future of children. 3rd World Congress on Child & Youth Health. Vancouver, British Columbia. May 11, 2003 CIHR and Human Sciences. Congress on the Humanities and Social Sciences. Halifax, Nova Scotia, May 31, 2003 Health Research in Canada: New Visions, New Structures. Tribute to Sir George Radda, U.K. Medical Research Council. London, United Kingdom. September 4, 2003 Genomics, Public Policy and Global Health. Genome Policy Course, Canadian Program on Genomics and Global Health, Joseph L. Rotman School of Management, University of Toronto. Toronto, Ontario. September 29, 2003 From Sovereign Silos to Borderless Domains. Canadian Association of Deans of Education. Ottawa, Ontario. October 22, 2003 The Global Revolution in Health Research. Keynote Address, The Gairdner Foundation

International Awards Gala. Toronto, Ontario. October 23, 2003 Improving the Healthcare of Children and Youth: ‘How do we effectively partner with key

organizations?’ Paediatric Chairs of Canada Fall Meeting and Research Symposium. Toronto, Ontario. November 6, 2003

CIHR and Health Research: Exceptional Value for Canadians. Keynote Address, Official opening of the Victoria Research Laboratories. London, Ontario. November 21, 2003

Strengthening the Foundations: Health Services and Policy Research – Canadian Health Care. CIHR Institute of Health Services and Policy Research Annual Symposium. Montreal, Quebec.

November 23, 2003 Financing Health Research: The Canadian Perspective. International Symposium on Medical

Research Funding – Vision for the 21st Century, Swedish Research Council. Stockholm, Sweden. January 14, 2004

Embryonic Stem Cell Research: Legal and Ethical Issues. International Symposium on Medical Research Funding – Vision for the 21st Century, Swedish Research Council. Stockholm, Sweden. January 14, 2004

Health Research: At the Nexus of Health, the Health System, and the Life Sciences Sector.

22

National Research Forum for Young Investigators in Circulatory and Respiratory Health. Winnipeg. May 6, 2004

HIV/AIDS and CIHR: Harnessing Research to Address a Major Health Challenge. Keynote Address, 13th Annual Canadian Conference on HIV/AIDS Research, Canadian Association for HIV Research. Montreal. May 13, 2004

CIHR and UBC: The Inaugural CIHR Visiting Presidency at UBC. University of British Columbia. May 17, 2004

The Promise of the Health Science in the 21st Century. The Canadian Academy of Health Sciences Inaugural Meeting, Keynote Address. Vancouver. September 21, 2005

Transforming Health Care in the 21st Century. NRC 6th Annual General Meeting of the Genomics and Health Initiative, Keynote Address. Ottawa. September 27, 2005

The Canadian Club of Toronto, luncheon speaker. Toronto. March 26, 2007 ‘Global Science for the Global Village’, World Science Forum, Budapest, Hungary. November

2007 Publications and Articles 1. Onodera, K., Rolfe, B. and Bernstein, A. (1970) Demonstration of missing membrane

proteins in deletion mutants of E. coli K12. Biochem. Biophys. Res. Commun. 39:969-975. 2. Rolfe, B., Sedgwick, J., Onodera, K., Bernstein, A. and Guest, J.R. (1971) Isolation of

plaque forming lambda phages which carry bacterial genes involved in the functional organization of the cell membrane. Biochem. Biophys. Res. Commun. 43:984-993.

3. Bernstein, A. (1972) A genetic analysis of the tol A,B locus of Escherichia coli K12. Ph.D. Thesis.

4. Bernstein, A., Rolfe, B. and Onodera, K. (1972) Pleiotropic properties and genetic organization of the tolA,B locus of Escherichiacoli K-12. J. Bacteriol. 112:74-83.

5. Bernstein, A., Rolfe, B. and Onodera, K. (1973) The E. coli cell surface: Isolation of lambda transducing phages carrying the tolPAB cluster. Molec. Gen. Genet. 121:325-335.

6. Bernstein, A. (1973) The E. coli cell surface: On the genetic organization of the tol PAB gene cluster. Molec. Gen. Genet. 123:111-121.

7. Bernstein, A. and Balduzzi, P.C. (1976) Virus-cell relationships: RNA tumour viruses. In: Scientific Foundations of Oncology (T. Symington and R.L. Carter, eds.), W. Heinemann, London, pp. 365-372.

8. Collins, J.J., Destree, A.T., Marshall, C.J., Bernstein, A. and MacPherson, I.A. (1976) Chromosomally depleted interspecific hybrid cell clones selected with cytotoxic antisera: Utilization in the study of control of murine leukemia virus host-range. J. Supramol. Struct. 4:71-88.

9. Bernstein, A., Boyd, A.S., Crichley, V. and Lamb, V. (1976) Induction and inhibition of Friend leukemic cell differentiation: The role of membrane-active compounds. In: Biogenesis and Turnover of Membrane Macromolecules (J.S. Cook, ed.), Raven Press, N.Y., pp. 145-159.

10. Bernstein, A., MacCormick, R. and Martin, G.S. (1976) Transformation-defective mutants of avian sarcoma viruses: The genetic relationship between conditional and nonconditional mutants. Virology 70:206-209.

11. Bernstein, A., Hunt, D.M., Crichley, V. and Mak, T.W. (1976) Induction by ouabain of hemoglobin synthesis in cultured Friend erythroleukemic cells. Cell 9:375-381.

23

12. Loritz, F., Bernstein, A. and Miller, R.G. (1977) Early and late volume changes during erythroid differentiation of cultured Friend leukemic cells. J. Cell. Physiol. 90:423-437.

13. Bernstein, A., Mak, T.W. and Stephenson, J.R. (1977) The Friend virus genome: Evidence for the stable association of MuLV sequences and sequences involved in erythroleukemic transformation. Cell 12:287-294.

14. Mager, D. and Bernstein, A. (1978) Early transport changes during erythroid differentiation of Friend leukemic cells. J. Cell. Physiol. 94:275-286.

15. Mak, T.W., Penrose, D., Gamble, C. and Bernstein, A. (1978) The Friend spleen focus-forming virus (SFFV) genome: Fractionation and analysis of SFFV and helper virus-related sequences. Virology 87:73-80.

16. MacDonald, M.E., Letarte, M. and Bernstein, A. (1978) Erythrocyte membrane antigen expression during Friend cell differentiation: Analysis of two non-inducible variants. J. Cell. Physiol. 96:291-301.

17. Mak, T.W., Penrose, D., Gamble, C. and Bernstein, A. (1978) The Friend spleen focus forming virus genome. In: Oncogenic Viruses and Host Cell Genes. (Y. Ikawa and T. Odaka, eds.) Academic Press, New York, pp. 183-193.

18. Bernstein, A., Mager, D.L., MacDonald, M., Letarte, M., Loritz, F., McCutcheon, M., Miller, R.G. and Mak, T.W. (1978) The cell surface and the control of Friend-cell differentiation. In: Differentiation of Normal and Neoplastic Hematopoietic Cells. Cold Spring Harbor Laboratory Press, New York, pp. 249-260.

19. Mager, D. and Bernstein, A. (1978) The program of Friend cell erythroid differentiation: Early changes in Na+/K+ ATPase function. J. Supramolecular Structure 8:431-438.

20. Mager, D.L., MacDonald, M.E. and Bernstein, A. (1979) Growth in high-K+ medium induces Friend cell differentiation. Dev. Biol. 70:268-273.

21. McCool, D., Mak, T.W. and Bernstein, A. (1979) Cellular regulation in Friend virus induced erythroleukemia: Studies with anemic mice of genotype S1/S1d. J. Exp. Med. 149:837-846.

22. Bernstein, A., Gamble, C., Penrose, D. and Mak, T.W. (1979) Presence and expression of Friend erythroleukemia virus-related sequences in normal and leukemic mouse tissues. Proc. Natl. Acad. Sci.U.S.A. 76:4455-4459.

23. Mager, D. and Bernstein, A. (1979) The role of heme in the regulation of the late program of Friend cell erythroid differentiation. J. Cell. Physiol. 100:467-479.

24. Mak, T.W., Axelrad, A.A. and Bernstein, A. (1979) Fv-2 locus controls expression of Friend spleen focus-forming virus-specific sequences in normal and infected mice. Proc. Natl. Acad. Sci. U.S.A. 76:5809-5812.

25. Crichley, V., Mager, D. and Bernstein, A. (1980) Colchicine resistant Friend cells: Application to the study of actinomycin D induced erythroid differentiation. J. Cell. Physiol. 102:63-70.

26. Mak, T.W., Gamble, C.L., MacDonald, M.E. and Bernstein, A. (1980) Host control of sequences specific to Friend erythroleukemia virus in normal and leukemic mice. Cold Spring Harbor Symposia on Quantitative Biology 44:893-899.

27. MacDonald, M.E., Reynolds, Jr., F.H., Van de Ven, W.J.M., Stephenson, J.R., Mak, T.W. and Bernstein, A. (1980) Anemia- and polycythemia-inducing isolates of Friend spleen focus-forming virus. Biological and molecular evidence for two distinct viral genomes. J. Exp. Med. 151:1477-1492.

24

28. MacDonald, M.E., Mak, T.W. and Bernstein, A. (1980) Erythroleukemia induction by replication-competent type C viruses cloned from the anemia- and polycythemia-inducing isolates of Friend leukemia virus. J. Exp. Med. 151:1493-1503.

29. Bernstein, A., MacDonald, M.E., Mager, D. and Mak, T.W. (1980) Host and viral genes in Friend leukemia. In: In vivo and in vitro erythropoiesis: The Friend system (G.B. Rossi, ed.) Elsevier/North-Holland Biomedical Press, Amsterdam, pp. 323-331.

30. Mager, D. and Bernstein, A. (1980) Phorbol ester tumor promoters block the transition from the early to the heme-dependent late program of Friend cell differentiation. J. Cell. Physiol. 105:519-526.

31. Letarte, M., Addis, J., MacDonald, M.E., Bernstein, A. and Lake, P. (1980) Demonstration with monoclonal antibody of the glycoprotein nature of Thy-1.2 alloantigen. Can. J. Biochem. 58:1026-1032.

32. Mager, D., Mak, T.W. and Bernstein, A. (1980) Friend leukaemia virus-transformed cells, unlike normal stem cells, form spleen colonies in Sl/Sld mice. Nature 288:592-594.

33. MacDonald, M.E., Johnson, G.R. and Bernstein, A. (1981) Different pseudotypes of Friend spleen focus-forming virus induce polycythemia and erythropoietin-independent colony formation in serum-free medium. Virology 110:231-236.

34. Mager, D., Mak, T.W. and Bernstein, A. (1981) Quantitative colony method for tumorigenic cells transformed by two distinct strains of Friend leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 78:1703-1707.

35. Mager, D., MacDonald, M.E., Robson, I.B., Mak, T.W. and Bernstein, A. (1981) Clonal analysis of the late stages of erythroleukemia induced by two distinct strains of Friend leukemia virus. Mol. Cell. Biol. 1:721-730.

36. Yamamoto, Y., Gamble, C.L., Clark, S.P., Joyner, A., Shibuya, T., MacDonald, M.E., Mager, D., Bernstein, A. and Mak, T.W. (1981) Clonal analysis of early and late stages of erythroleukemia induced by molecular clones of integrated spleen focus-forming virus. Proc. Natl. Acad. Sci. U.S.A. 78:6893-6897.

37. Joyner, A., Yamamoto, Y. and Bernstein, A. (1981) Construction and transfer of recombinant retrovirus clones carrying the HSV-1 thymidine kinase gene. In: Developmental Biology Using Purified Genes (D. Brown and C.F. Fox, eds.). Academic Press, New York, pp. 535-546.

38. Joyner, A., Yamamoto, Y. and Bernstein, A. (1982) Retrovirus long terminal repeats activate expression of coding sequences for the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. U.S.A. 79:1573-1577.

39. Bernstein, A., Mowat, M., Duke-Cohan, J., Mager, D. and Yamamoto, Y. (1983) Molecular and cellular aspects of Friend Leukemia. In: Tumor Viruses and Differentiation (E. Scolnick and A. Levine, eds.). Alan R. Liss, Inc., N.Y. pp 341-348.

40. Mowat, M. and Bernstein, A. (1983) Linkage of the Fv-2 gene to a newly reinserted ecotropic retrovirus in Fv-2 congenic mice. J. Virol. 47:471-477.

41. Joyner, A.L. and Bernstein, A. (1983) Retrovirus transduction: Generation of infectious retroviruses expressing dominant and selectable genes is associated with in vivo recombination and deletion events. Mol. Cell. Biol. 3:2180-2190.

42. Joyner, A.L., and Bernstein, A. (1983) Retrovirus transduction: Segregation of the viral transforming function and the herpes simplex virus tk gene in infectious Friend spleen focus-forming virus thymidine kinase vectors. Mol. Cell. Biol. 3:2191-2202.

25

43. Joyner, A.L., Keller, G., Phillips, R.A. and Bernstein, A. (1983) Retrovirus transfer of a bacterial gene into mouse hematopoietic progenitor cells. Nature 305:556-558.

44. Rubin, J.S., Joyner, A.L., Bernstein, A. and Whitmore, G.F. (1983) Molecular identification of a human DNA repair gene following DNA-mediated gene transfer. Nature 306:206-208.

45. Rubin, J.S., Joyner, A.L., Bernstein, A. and Whitmore, G.F. (1983) DNA-mediated gene transfer of a human DNA repair gene(s) into DNA repair deficient Chinese hamster ovary cells. In: Cellular Responses to DNA Damage (E.C. Friedberg and B.R. Bridges, eds.) A.R. Liss Inc., New York, pp 615-624.

46. Teich, N., Wyke, J., Mak, T., Bernstein, A. and Hardy, W. (1984) Pathogenesis of retrovirus induced disease. In: RNA Tumor Viruses, 2nd ed. (R. Weiss, N. Teich, H. Varmus, and J. Coffin, eds.). Cold Spring Harbor Laboratory Press, New York, pp. 785-998.

47. Joyner, A.L. and Bernstein, A. (1984) Development of Friend spleen focus-forming virus as a mammalian gene transfer vector. In: Gene Transfer and Cancer (M.L. Pearson and N.L. Sternberg, eds.), Progress in Cancer Research and Therapy, Vol. 30, Raven Press, New York, pp. 89-96.

48. Mak, T. and Bernstein, A. (1984) Modulation of the haematopoietic system by murine retroviruses. Clinics in Haematology 13: 447-459.

49. Rubin, J.S., Prideaux, V.R., Huntington, F.W., Dulhanty, A.M., Whitmore, G.F. and Bernstein, A. (1985) Molecular cloning and chromosomal localization of DNA sequences associated with a human DNA repair gene. Mol. Cell. Biol. 5:398-405.

50. Bernstein, A., Berger, S., Huszar, D. and Dick, J. (1985) Gene transfer with retrovirus vectors. In: Genetic Engineering: Principles and Methods, Vol. 7 (J.K. Setlow and A. Hollaender, eds.), Plenum Press, New York, pp. 235-261.

51. Berger, S.A. and Bernstein, A. (1985) Characterization of a retrovirus shuttle vector capable of either proviral integration or extrachromosomal replication in mouse cells. Mol. Cell. Biol. 5:305-312.

52. Mager, D.L. and Bernstein, A. (1985) Induction of clonogenic and erythroleukemic cells by different helper virus pseudotypes of Friend spleen focus-forming virus. Virology 141:337-341.

53. Mowat, M., Cheng, A., Kimura, N., Bernstein, A. and Benchimol, S. (1985) Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 314:633-636.

54. Robson, I., Mowat, M. and Bernstein, A. (1985) Tissue-specific expression of the newly acquired ecotropic emv-18 provirus in Fv-2 congenic mice. J. Virol. 55:54-59.

55. Dick, J.E., Magli, M.C., Huszar, D., Phillips, R.A. and Bernstein, A. (1985) Introduction of a selectable gene into primitive stem cells capable of long term reconstitution of the hemopoietic system of W/Wv mice. Cell 42:71-79.

56. Berger, S.A., Sanderson, N., Bernstein, A. and Hankins, W.D. (1985) Induction of the early stages of Friend erythroleukemia with helper-free Friend spleen focus-forming virus. Proc. Natl. Acad. Sci. U.S.A. 82:6913-6917.

57. Huszar, D., Balling, R., Kothary, R., Magli, M.C., Hozumi, N., Rossant, J. and Bernstein, A. (1985) Insertion of a bacterial gene into the mouse germ line using an infectious retrovirus vector. Proc. Natl. Acad. Sci. U.S.A. 82:8587-8591.

58. Dick, J.E., Magli, M.C., Phillips, R.A. and Bernstein, A. (1986) Genetic manipulation of

26

hematopoietic stem cells with retrovirus vectors. Trends Genet. 2:165-170. 59. Belmont, J., Henkel-Tiggs, J., Chang, S., Wager-Smith, K., Kellems, R., Dick, J., Magli,

M.C., Phillips, R., Bernstein, A. and Caskey, C.T. (1986) Expression of human adenosine deaminase in murine hematopoietic progenitor cells following retroviral transfer. Nature 322:385-387.

60. Bernstein, A., Dick, J., Huszar, D., Robson, I., Rossant, J., Magli, M.C., Estrov, Z., Freedman, M. and Phillips, R. (1986) Genetic engineering of mouse and human stem cells. Cold Spring Harb. Symp. Quant. Biol. 51:1083-1091.

61. Dick, J., Magli, M.C., Estrov, Z., Freedman, M., Phillips, R. and Bernstein, A. (1987) Retrovirus-mediated gene transfer and expression in murine and human hematopoietic stem cells. In: Progress in Bone Marrow Transplantation, UCLA Symposium on Molecular and Cellular Biology, Liss, New York, pp. 951-962.

62. Magli, M.C., Dick, J., Huszar, D., Bernstein, A., and Phillips, R. (1987) Modulation of gene expression in multiple hematopoietic cell lineages following retroviral vector gene transfer. Proc. Natl. Acad. Sci. U.S.A. 84:789-793.

63. Rovinski, B., Munroe, D., Peacock, J., Mowat, M. Bernstein, A., and Benchimol, S. (1987) Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol. Cell. Biol. 7:847-853.

64. Chow, V., Ben-David, Y., Bernstein, A. Benchimol, S. and Mowat, M. (1987) Multi-stage Friend erythroleukemia: Independent origin of tumor clones with normal or rearranged p53 cellular oncogenes. J. Virol. 61:2777-2781.

65. Wu, D-D., Huszar, D., Dick, J.E., Bernstein, A., and Phillips, R.A. (1987) High efficiency gene transfer and expression in normal murine B lymphocytes. J. Immunol. Methods 101:279-285.

66. Rovinski, B., Peacock. J., Mowat, M., Bernstein, A. and Benchimol, S. (1987) Isolation and expression of a rearranged p53 gene from mouse erythroleukemia cells encoding a stable protein. In: Recent Advances in Leukemia and Lymphoma, UCLA Symposium on Molecular and Cellular Biology, Liss, New York, pp 31-41.

67. Breitman, M.L., Clapoff, S., Rossant, J., Tsui, L.-C., Glode, M., Maxwell, I.H., and Bernstein, A. (1987) Genetic ablation: Targeted expression of a toxin gene causes microphthalmia in transgenic mice. Science 238:1563-1565.

68. Munroe, D.G., Rovinski, B., Bernstein, A. and Benchimol, S. (1988) Loss of a highly conserved domain on p53 as a result of gene deletion during Friend virus-induced erythroleukemia. Oncogene 2:621-624.

69. Ben-David, Y., Prideaux, V.R., Chow, V., Benchimol, S., and Bernstein, A. (1988) Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene 3:179-185.

70. Korczak, B., Robson, I., Lamarche, C., Bernstein, A., and Kerbel, R.S. (1988) Genetic tagging of tumor cells with retroviral vectors: clonal analysis of tumor growth and metastasis in vivo. Mol. Cell. Biol. 8:3143-3149.

71. Chabot, B., Stephenson, D.A., Chapman, V.M., Besmer, P. and Bernstein, A. (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335:88-89.

72. Biology of Growth Factors: Molecular Biology, Oncogenes, Signal Transduction and Clinical Implications. Edited by Jeffrey E. Kudlow, David H. MacLennan, Alan Bernstein, and

27

Avrum I. Gotlieb. 1988, Plenum Press, New York. 73. Maxwell, I.H., Glode, L.M., Maxwell, F., Harrison, G.S., Breitman, M.L., Rombola, H.,

Coulson, D.-M., and Bernstein, A. (1989) Targeted cell suicide by toxin gene expression. UCLA Symposium on Molecular and Cellular Biology, Gene Transfer and Gene Therapy 88:189-204.

74. Ellis, J. and Bernstein, A. (1989) Gene targeting with retroviral vectors: recombination by gene conversion into regions of nonhomology. Mol. Cell. Biol. 9:1621-1627.

75. Bernstein, A. and Breitman, M.L. (1989) Genetic ablation in transgenic mice. Mol. Biol. Med. 6:523-530.

76. Yee, S-P., Mock, D., Maltby, V., Silver, M., Rossant, J., Bernstein, A. and Pawson, T. (1989) Cardiac and neurological abnormalities in v-fps transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 86:5873-5877.

77. Ellis, J. and Bernstein, A. (1989) Retrovirus vectors containing an internal attachment site: evidence that circles are not intermediates to murine retrovirus integration. J. Virol. 63:2844-2846.

78. Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T, and Bernstein, A. (1989) High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9:3982-3991.

79. Breitman, M.L., Bryce, D.M., Giddens, E., Clapoff, S., Goring, D., Tsui, L.-C., Klintworth, G.K. and Bernstein, A. (1989) Analysis of lens cell fate and eye morphogenesis in transgenic mice ablated for cells of the lens lineage. Development 106:457-463.

80. Ben David, Y. and Bernstein, A. (1989) Friend virus-induced erythroleukemia: A multistage malignancy. In: Viral Oncogenesis and Cell Differentiation: The Contributions of Charlotte Friend, Annals of the New York Academy of Sciences 567:165-170.

81. Huszar, D., Ellis, J. and Bernstein, A. (1989) A rapid and accurate method for determining the titer of retrovirus vectors lacking a selectable marker. Technique 1:28-32.

82. Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervonne, M. Bernstein, A. and Besmer, P. (1989) Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice – evidence for an impaired c-kit kinase in mutant mice. Genes Dev. 3:816-826.

83. Yee, S-P., Mock, D., Greer, P., Maltby, V., Rossant, J., Bernstein, A. and Pawson, T. (1989) Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase. Mol. Cell. Biol. 9:5491-5499.

84. Benchimol, S., Munroe, D.G., Rovinski, B., Ben David, Y., and Bernstein, A. (1989) Inactivation of the cellular p53 gene in Friend virus-transformed erythroleukemia cell lines. In: Vectors as Tools for the Study of Normal and Abnormal Growth and Differentiation, (H. Lother, R. Dernick, and W. Ostertag, eds.), Springer-Verlag, Heidelberg, pp. 409-417.

85. Bernstein, A., Chabot, B., Dubreuil, P., Reith, A., Nocka, K., Majumder, S., Ray, P., and Besmer, P. (1989) The mouse W/c-kit locus. CIBA Foundation No. 148, Molecular Control of Haemopoiesis. pp. 158-172.

86. Ben-David, Y., Giddens, E. and Bernstein, A. (1990) Identification and mapping of a common proviral integration site Fli -1 in erythroleukemic cells induced by Friend murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 87:1332-1336.

87. Greer, P., Maltby, V., Rossant, J., Bernstein, A. and Pawson, T. (1990) Myeloid expression of the human c-fps/fes proto-oncogene in transgenic mice. Mol. Cell. Biol. 10:2521-2527.

28

88. Steeg, C.M., Ellis, J. and Bernstein, A. (1990) Introduction of specific point mutations into RNA Polymerase II by gene targeting in mouse embryonic stem cells: evidence for a DNA mismatch repair mechanism. Proc. Natl. Acad. Sci. U.S.A. 87:4680-4684.

89. Breitman, M.L., Rombola, H., Maxwell, I.H. Klintworth, G.K., and Bernstein, A. (1990) Genetic ablation in transgenic mice with an attenuated diphtheria toxin A gene. Mol. Cell. Biol. 10:474-479.

90. Reith, A., Rottapel, R., Giddens, E., Brady, C., Forrester, L. and Bernstein, A. (1990) W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev. 4:390-400.

91. Pawson, A.J., and Bernstein, A. (1990) Receptor tyrosine kinases: Genetic evidence for their role in Drosophila and mouse development. Trends Genet. 6:350-356.

92. Ben-David, Y., Lavigueur, A., Cheong, G.Y. and Bernstein, A. (1990) Insertional inactivation of the p53 gene during Friend leukemia: A new strategy for identifying tumor suppressor genes. New Biol. 2:1015-1023.

93. Dubreuil, P., Rottapel, R., Reith, A.D., Forrester, L.M. and Bernstein, A. (1990) The mouse W/c-kit locus: A mammalian gene that controls the development of three distinct cell lineages. In: Cell Lineages in Development, Ann. N.Y. Acad. Sci., 599:58-65.

94. Joshi, S., Van Brunschot, A., Robson, I. and Bernstein, A. (1990) Efficient replication, integration, and packaging of retroviral vectors with modified long terminal repeats containing the packaging signal. Nucl. Acids Res. 18:4223-4226.

95. Bernstein, A., Forrester, L., Reith, A., Dubreuil, P. and Rottapel, R. (1991) The murine W/c-kit and Steel loci and the control of hematopoiesis. Seminars in Hematology 28:138-142.

96. Dubreuil, P., Forrester, L., Rottapel, R., Fujita, J. and Bernstein, A. (1991) The c-fms gene complements the mitogenic defect in mast cells derived from mutant W mice but not mi (microphthalmia) mice. Proc. Natl. Acad. Sci. U.S.A. 88:2341-2345.

97. Ben David, Y., Letwin, K., Tannock, L., Bernstein, A. and Pawson, T. (1991) A mammalian protein kinase with potential for serine/threonine and tyrosine phosphorylation is related to cell cycle regulators. EMBO J. 10:317-325.

98. Ben-David, Y., Giddens, E.G., Letwin, K. and Bernstein, A. (1991) Erythroleukemia induction by Friend murine leukemia virus: Insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1. Genes Dev. 5:908-918.

99. Rottapel, R., Reedijk, M., Williams, D.E., Lyman, S.E., Anderson, D.M., Pawson, T. and Bernstein, A. (1991) The Steel/W transduction pathway: Kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol. Cell. Biol. 11:3043-3051.

100. Lavigueur, A. and Bernstein, A. (1991) p53 transgenic mice: Accelerated erythroleukemia induction by Friend virus. Oncogene 6:2197-2201.

101. Reith, A.D., Ellis , C., Lyman, S.D., Anderson, D.M., Williams, D.E., Bernstein, A. and Pawson, T. (1991) Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 10:2451-2459.

102. Reith, A. and Bernstein, A. (1991) Molecular basis of mouse developmental mutants. Genes Dev. 5:1115-1123.

103. Olivieri, N., Grunberger, T., Ben-David, Y., Ng, J., Williams, D.E., Lyman, S., Anderson, D.M., Axelrad, A.A., Correa, P., Bernstein, A. and Freedman, M.H. (1991) Diamond-

29

Blackfan anemia: Heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus. Blood 78:2211-2215.

104. Joshi, S., van Brunschot, A., Asad, S., van der Elst, I., Read, S.E. and Bernstein, A. (1991) Inhibition of Human Immunodeficiency Virus Type 1 Multiplication by Antisense and Sense RNA Expression. J. Virol. 65:5524-5530.

105. Forrester, L.M., Bernstein, A., Rossant, J. and Nagy, A. (1991) Long-term reconstitution of the mouse hemopoietic system by embryonic stem cell-derived foetal liver. Proc. Natl. Acad. Sci. U.S.A. 88:7514-7517.

106. Motro, B., van der Kooy, D., Rossant, J., Reith, A. and Bernstein, A. (1991) Contiguous patterns of c-kit and steel expression: analysis of mutations at the W and Sl loci. Development 113:1207-1221.

107. Ben-David, Y. and Bernstein, A. (1991) Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 66:831-834.

108. Reith, A. and Bernstein, A. (1991) Molecular Biology of the W and Steel Loci. In: Genome Analysis 3: Genes & Phenotypes (K. Davies and S. Tilghman, eds.), Cold Spring Harbor Laboratory Press, New York, pp. 105-133.

109. Breitman, M.L. and Bernstein, A. (1992) Engineering cellular deficits in transgenic mice by genetic ablation. In: Transgenic Mice in Biology and Medicine. (F. Grosveld & G. Kollias, eds.), Academic Press, London, pp. 127-146.

110. Ben-David, Y., Bani, M.R., Chabot, B., De Koven, A. and Bernstein, A. (1992) Retroviral insertions downstream of the heterogeneous nuclear ribonucleoprotein A1 gene in erythroleukemia cells: Evidence that A1 is not essential for cell growth. Mol. Cell. Biol. 12:4449-4455.

111. Forrester, L.M., Brunkow, M. and Bernstein, A. (1992) Proto-oncogenes in mammalian development. Curr. Opin. Genet. Dev. 2:38-44 (ed. H.E. Varmus).

112. Meininger, C.J., Yano, H., Rottapel, R., Bernstein, A., Zsebo, K.M. and Zetter, B.R. (1992) The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79:958-963.

113. Miller, B.A., Perrine, S.P., Bernstein, A., Lyman, S.D., Williams, D.E., Bell, L.L. and Olivieri, N.F. (1992) Influence of Steel factor on fetal hemoglobin synthesis in sickle cell anemia. Blood 79:1861-1868.

114. McGlade, C.J., Ellis, C., Reedijk, M., Anderson, D., Mbamalu, G., Reith, A.D., Panayotou, G., End, P., Bernstein, A., Kazlauskas, A., Waterfield, M.D. and Pawson, T. (1992) SH2 domains of the p85 subunit of phosphatidylinositol 3'-kinase regulate binding to growth factor receptors. Mol. Cell. Biol. 12:991-997.

115. Klein, K.L., Klintworth, G.K., Bernstein, A. and Breitman, M.L. (1992) Embryology and morphology of microphthalmia in transgenic mice expressing a F-crystallin/diphtheria toxin A hybrid gene. Lab. Invest. 67:31-41.

116. Letwin, K., Mizzen, L., Motro, B., Ben-David, Y., Bernstein, A. and Pawson, T. (1992) A mammalian dual specificity protein kinase, Nek1, is related to the NIMA cell cycle regulator and highly expressed in meiotic germ cells. EMBO J. 11:3521-3531.

117. Bernstein, A. (1992) Molecular control of hematopoietic stem cell function. In: Current Opinion in Oncology 4(suppl 1):S5-S7.

118. Irish, J.C. and Bernstein, A. (1993) Oncogenes in head and neck cancer. Laryngoscope 103:42-52.

119. Reith, A.D., Ellis, C., Maroc, N., Pawson, T., Bernstein, A. and Dubreuil, P. (1993) 'W'

30

mutant forms of the Fms receptor tyrosine kinase act in a dominant manner to suppress CSF-1 dependent cellular transformation. Oncogene 8:45-53.

120. Zhang, L., Lemarchandel, V., Romeo, P-H., Ben-David, Y., Greer, P. and Bernstein, A. (1993) The Fli-1 proto-oncogene, involved in erythroleukemia and Ewing's sarcoma, encodes a transcriptional activator with DNA-binding specificities distinct from other Ets family members. Oncogene 8:1621-1630.

121. Bernstein, A. (1993) Molecular genetic approaches to the elucidation of hematopoietic stem cell function. Stem Cells 11(suppl 2):31-35.

122. Blouin, R. and Bernstein, A. (1993) The White spotting and Steel hereditary anemias of the mouse. In: Clinical Disorders and Experimental Models of Erythropoietic Failure (S.A. Feig and M.H. Freedman, eds.), CRC Press, Inc., Boca Rator, pp. 157-173.

123. Bernstein, A. (1993) The W/c-kit and Steel loci. In: Application of Basic Science to Hematopoiesis and Treatment of Disease (D. Thomas, ed.), Raven Press, New York, pp. 71-82.

124. Lee, J.M. and Bernstein, A. (1993) p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. U.S.A. 90:5742-5746.

125. Motro, B. and Bernstein, A. (1993) Dynamic changes of ovarian c-kit and Steel expression during the estrous reproductive cycle. Developmental Dynamics 197:69-79.

126. Howard, J.F., Yousefi, S., Cheong, G., Bernstein, A. and Ben-David, Y. (1993) Temporal order and functional analysis of mutations within the Fli-1 and p53 genes during the erythroleukemias induced by F-MuLV. Oncogene 8:2721-2729.

127. Bernstein, A. (1993) Receptor tyrosine kinases and the control of hematopoiesis. Seminars in Developmental Biology 4:351-358.

128. Piao, X., Curtis, J.E., Minden, M.D. and Bernstein, A. (1994) Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood 83:476-481.

129. Bernstein, A., Klüppel, M. and Brunkow, M. (1994) Molecular genetics of the Kit receptor/Steel factor signalling pathway. In: Cytokines and Receptors, Proceedings of the Third International Mochida Memorial Symposium on Horizon in Cytokine Research, Shobunsha Co., Ltd., Tokyo, Chapter 1, pp. 3-16.

130. Lee, J.M., Abrahamson, J.L.A., Kandel, R., Donehower, L.A. and Bernstein, A. (1994) Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731-3736.

131. Lee, J.M., Abrahamson, J.L.A. and Bernstein, A. (1994) DNA damage, oncogenesis and the p53 tumour-suppressor gene. Mutation Research 307:573-581.

132. Greer, P., Haigh, J., Mbamalu, G., Khoo, W., Bernstein, A. and Pawson, T. (1994) The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice. Mol. Cell. Biol. 14:6755-6763.

133. Bernstein, A. and Motro, B. (1994) Kit (stem cell or Steel factor) receptor. In: Guidebook to Cytokines and Their Receptors, (N.A. Nicola, ed.), Oxford University Press, Oxford, pp. 180-182.

134. Zmuidzinas, A., Fischer, K.-D., Lira, S.A., Forrester, L., Bryant, S., Bernstein, A. and Barbacid, M. (1995) The vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J. 14:1-11.

135. Brunkow, M.E., Nagle, D.L., Bernstein, A. and Bucan, M. (1995) A 1.8 Mb YAC contig spanning three members of the receptor tyrosine kinase gene family (Pdgfra, Kit, and Flk1)

31

on mouse chromosome 5. Genomics 25:421-432. 136. Huizinga, J.D., Thuneberg, L. Klüppel, M., Malysz, J., Mikkelsen, H.B. and Bernstein, A.

(1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373:347-349.

137. Kao, K. and Bernstein, A. (1995) Expression of Xkl-1, a Xenopus gene related to mammalian c-kit, in dorsal embryonic tissue. Mechanisms of Development 50:57-69.

138. Zhang, L., Eddy, A., Teng, Y-T., Fritzler, M., Klüppel, M., Melet, F. and Bernstein, A. (1995) An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factors. Mol. Cell. Biol. 15:6961-6970.

139. Fischer, K.-D., Zmuidzinas, A., Gardner, S., Barbacid, M., Bernstein, A. and Guidos, C. (1995). Defective T cell receptor signaling and positive selection of Vav-deficient CD4+CD8+ thymocytes. Nature 374:474-477.

140. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A. and Donehower, L.A. (1995) A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics 9:305-311.

141. Lee, J. and Bernstein, A. (1995) Apoptosis, cancer and the p53 tumour suppressor gene. Cancer & Metastasis Reviews 14:149-161.

142. Paulson, R.F. and Bernstein, A. (1995) Receptor tyrosine kinases and the regulation of hematopoiesis. Sem. Immun. 7:267-277.

143. Puri, M.C., Rossant, J., Alitalo, K., Bernstein, A. and Partanen, J. (1995) The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:5884-5891.

144. Abrahamson, J.L.A., Lee, J.M. and Bernstein, A. (1995) Regulation of p53-mediated apoptosis and cell cycle arrest by Steel Factor. Mol. Cell. Biol. 15:6953-6960.

145. Bernstein, A., Correll, P., Paulson, R. and Potter, M. (1996) In vitro and in vivo approaches to the molecular analysis of mouse hematopoiesis. In: Mammalian Development, (Lonai, P., ed.), Harwood Academic Publishers, Amsterdam, pp. 101-134.

146. Paulson, R.F., Vesely, S., Siminovitch, K.A. and Bernstein, A. (1996) Signaling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase PTP1C. Nature Genetics 13:309-315.

147. Piao, X., van der Geer, P., Paulson, R.F., Pawson, T. and Bernstein, A. (1996) Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. U.S.A. 93:14665-14669.

148. Melet, F., Motro, B., Rossi, D.J., Zhang, L. and Bernstein, A. (1996) Generation of a novel Fli-1 protein by gene targeting leads to a defect in thymus development and a delay in Friend virus-induced erythroleukemia. Mol. Cell. Biol. 16:2708-2718.

149. Piao, X. and Bernstein, A. (1996) A point mutation in the catalytic domain of c-Kit induces growth factor independence, tumorigenicity and differentiation of mast cells. Blood 87:3117-3123.

150. Forrester, L., Nagy, A., Sam, M., Watt, A., Stevenson, L., Bernstein, A., Joyner, A.L., and Wurst, W. (1996) An induction gene trap screen in embryonic stem cells: Identification of genes that respond to retinoic acid in vitro. Proc. Natl. Acad. Sci. U.S.A. 93:1677-1682.

151. Motro, B., Wojtowicz, J.M., Bernstein, A. and van der Kooy, D. (1996) Steel mutant mice are deficient in hippocampal learning but not long-term potentiation. Proc. Nat. Acad. Sci.

32

U.S.A. 93:1808-1813. 152. Sam, M., Wurst, W., Forrester, L., Vauti, F., Heng, H. and Bernstein, A. (1996) A novel

family of repeat sequences in the mouse genome responsive to retinoic acid. Mammalian Genome 7:741-748.

153. Partanen, J., Puri, M.C., Schwartz, L., Fischer, K.-D., Bernstein, A. and Rossant, J. (1996) Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 122:3013-3021.

154. Klüppel, M., Nagle, D.L., Bucan, M. and Bernstein, A. (1997) Long-range genomic rearrangements upstream of Kit dysregulate the developmental pattern of Kit expression in W57 and Wbanded mice and interfere with distinct steps in melanocyte development. Development 124:65-77.

155. Correll, P.H., Iwama, A., Tondat, S., Mayrhofer, G., Suda, T. and Bernstein, A. (1997) Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes and Function 1:69-83.

156. Nishina, H., Fischer, K.-D., Radvanyi, L., Shahinian, A., Hakem, R., Rubie, E.A., Bernstein, A., Mak, T.W., Woodgett, J.R. and Penninger, J.M. (1997) Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 ad CD3. Nature 385:350-353.

157. Potter, M.D., Shinpock, S.G., Popp, R.A., Popp, D.M., Godfrey, V., Carpenter, D.A., Bernstein, A., Johnson, D.K. and Rinchik, E.M. (1997) Mutations in the murine fitness 1 gene result in defective hematopoiesis. Blood 90:1850-1857.

158. Shalaby, F., Ho, J., Stanford, W.L., Fisher, K.-D., Schuh, A.C., Schwartz, L., Bernstein, A. and Rossant, J. (1997) A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89:981-990.

159. Klüppel, M., Donoviel, D., Brunkow, M.E., Motro, B. and Bernstein, A. (1997) Embryonic and adult expression patterns of the Tec tyrosine kinase gene suggest a role in megakaryocytopoiesis, blood vessel development and melanogenesis. Cell Growth & Differentiation 8:1249-1256.

160. Nishina, H., Bachmann, M., Oliveira-dos-Santos, A.J., Kozieradzki, I., Fischer, K.D., Odermatt, B., Wakeham, A., Shahinian, A., Takimoto, H., Bernstein, A., Mak, T.W., Woodgett, J.R., Ohashi, P.S. and Penninger, J.M. (1997) Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J. Exp. Med. 186:941-953.

161. Klüppel, M., Huizinga, J.D., Malysz and Bernstein, A. (1998) Developmental origin and Kit-dependent development of the interstitial cells of Cajal in the mammalian small intestine. Developmental Dynamics 211:60-71.

162. Fischer, K.-D., Kong, Y.-Y., Nishina, H., Tedford, K., Marengere, L.E.M., Kozieradzki, I., Sasaki, T., Starr, M., Chan, G., Gardener, S., Nghiem, M.P., Bouchard, D., Barbacid, M., Bernstein, A. and Penninger, J.M. (1998) Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Current Biology 8:554-562.

163. Sam, M., Wurst, W., Klüppel, M., Jin, O., Heng, H. and Bernstein, A. (1998) Aquarius, a novel gene isolated by gene trapping with an RNA-dependent RNA polymerase motif. Developmental Dynamics 212:304-317.

164. Paulson, R.F. and Bernstein, A. (1998) A genetic linkage map of the mouse Chromosome 9

33

region encompassing the Friend virus susceptibility gene 2 (Fv2). Mammalian Genome 9:381-384.

165. Stanford, W.L., Caruana, G., Vallis, K.A., Inamdar, M., Hidaka, M., Bautch, V.L., and Bernstein, A. (1998) Expression trapping: Identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. Blood 92:4622-4631.

166. Potter, M., Bernstein, A. and Lee, J.M. (1998) The wst gene regulates multiple forms of thymocyte apoptosis. Cellular Immunology 188:111-117.

167. Bernstein, A. (1998) Have you used an adeno vector ...... lately? Nature Genetics 18:303-304.

168. Donoviel, D.B., Donoviel, M.S., Fan, E., Hadjantonakis, A.-K. and Bernstein, A. (1998) Cloning and characterization of Sel-1l, a murine homolog of the C. elegans sel-1 gene. Mechanisms of Development 78:203-207.

169. Kong, Y.-Y., Fischer, K.-D., Bachmann, M.F., Mariathasan, S., Kozieradzki, I., Nghiem, M.P., Bouchard, D., Bernstein, A., Ohashi, P.S. and Penninger, J.M. (1998) Vav regulates peptide-specific apoptosis in thymocytes. J. Exp. Med. 188:2099-2111.

170. Arama, E., Yanai, A., Kilfin, G., Bernstein, A. and Motro, B. (1998) Murine NIMA-related kinases are expressed in patterns suggesting distinct functions in gametogenesis and a role in the nervous system. Oncogene 16:1813-1823.

171. Bennett, D.C., Trayner, I.D., Piao, X., Easty, D.J., Klüppel, M., Alexander, W.S., Wagner, E.F. and Bernstein, A. (1998) Recessive spotting: a linked locus that interacts with W/Kit but is not allelic. Genes to Cells 3:235-244.

172. Bernstein, A. and Shafir, S. (1999) Genes run in the family. Canadian Family Physician 45:13-15.

173. Donoviel, D.B. and Bernstein, A. (1999) SEL-1L maps to human chromosome 14, near the insulin-dependent diabetes mellitus locus 11. Genomics 56:232-233.

174. Hidaka, M., Caruana, G., Stanford, W.L., Sam, M., Correll, P.H., and Bernstein, A. (2000) Hzf and Hhl, two novel hematopoietic genes expressed in megakaryocytes identified by gene trapping in ES cells. Mechanisms of Development 90:3-15.

175. Hidaka, M., Stanford, W.L., and Bernstein, A. (1999) Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 96:7370-7375.

176. Puri, M.C., Partanen, J., Rossant, J. and Bernstein, A. (1999) Interaction of the TEK and TIE receptor kinases during cardiovascular development. Development 126:4569-4580.

177. Donoviel, D.B., Hadjantonakis, A.-K., Ikeda, M., Zheng, H., St. George-Hyslop, P. and Bernstein, A. (1999) Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes. Dev. 13:2801-2810.

178. Persons, D.A., Paulson, R.F., Loyd, M.R., Herley, M.T., Bodner, S.M., Bernstein, A., Correll, P.H. and Ney, P.A. (1999) Fv2 is a truncated form of the Stk/RON receptor tyrosine kinase. Nature Genetics 23:159-165.

179. Hart, A., Melet, F. and Bernstein, A. (2000) Fli -1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 13:167-177.

180. Dror, Y., Leaker, M., Caruana, G., Bernstein, A. and Freedman, M.H. (2000) Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis. Br. J. Haematol. 108:729-736.

34

181. Lourenssen, S., Motro, B., Bernstein, A. and Diamond, J. (2000) Defects in sensory nerve numbers and growth in mutant Kit and Steel mice. Neuroreport 11:1159-1165.

182. Zhang, Z., Nadeau, P., Song, W., Donoviel, D., Yuan, M., Bernstein, A. and Yankner, B.A. (2000) Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nat. Cell Biol. 2:463-465.

183. Sato, N., Urano, F., Yoon Leem, J., Kim, S.H., Li, M., Donoviel, D., Bernstein, A., Lee, A.S., Ron, D., Veselits, M.L., Sisodia, S.S. and Thinakaran, G. (2000) Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression. Nat. Cell Biol. 2:863-870.

184. Hart, A.H., Reventar, R. and Bernstein, A. (2000) Genetic analysis of ETS genes in C. elegans. Oncogene 19:6400-6408.

185. Caruana, G. and Bernstein, A. (2001) Craniofacial dysmorphogenesis including cleft palate in mice with an insertional mutation in the discs large gene. Mol. Cell. Biol. 21:1475-1483.

186. Bernstein, A., Shulman, J. and Caruana. G. (2001) W (White Spotting) locus. In: Encyclopedia of Genetics (L. Silver, ed.), Academic Press, New York, pp. 2125-2127.

187. Caruana. G. and Bernstein, A. (2001) Steel locus. In: Encyclopedia of Genetics (L. Silver, ed.), Academic Press, New York, pp. 1887-1888.

188. Berechid, B.E., Kitzmann, M., Foltz, D.R., Roach, A.H., Seiffert, D., Thompson, L.A., Olson, R.E., Bernstein, A., Donoviel, D.B. and Nye, J.S. (2002) Identification and characterization of presenilin-independent notch signaling. J. Biol. Chem. 277:8154-8165.

189. Vallis, K.A., Chen, Z., Stanford, W.L., Yu, M., Hill, R.P. and Bernstein, A. (2002) Identification of radiation-responsive genes in vitro using a gene trap strategy predicts for modulation of expression by radiation in vivo. Radiat. Res. 157:8-18.

190. Lutz, M.A., Gervais, F., Bernstein, A., Hattel, A.L. and Correll, P.H. (2002) STK receptor tyrosine kinase regulates susceptibility to infection with Listeria monocytogenes. Infect. Immun. 70:416-418.

191. Hitoshi, S., Alexson, T., Tropepe, V., Donoviel, D., Elia, A.J., Nye, J.S., Conlon, R.A., Mak, T.W., Bernstein, A. and van der Kooy, D. (2002) Notch pathway molecules are essential for the maintenance but not the generation of mammalian neural stem cells. Genes Dev. 16:846-858.

192. Kimura Y., Hart A., Hirashima, M., Wang, C., Holmyard, D., Pittman, J., Pang, XL, Jackson, C.W., and Bernstein, A. (2002) Zinc Finger Protein, Hzf, is Required for Megakaryocyte Development and Hemostasis. J. Exp. Med. 195:941-952.

193. Taniguchi, Y., Karlstrom, H., Lundkvist, J., Mizutani, T., Otaka, A., Vestling, M., Bernstein, A., Donoviel, D., Lendahl, U., and Honjo, T. (2002) Notch receptor cleavage depends on but is not directly executed by presenilins. Proc. Natl. Acad. Sci. U.S.A. 99:4014-4019.

194. Velazquez, L., Cheng, A.M., Fleming, H.E., Furlonger, C., Vesely, S., Bernstein, A., Paige, C.J., and Pawson, T. (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J. Exp. Med. 195:1599-1611.

195. Klocker, N., Bunn, R.C., Schnell, E., Caruana, G., Bernstein, A., Nicoll, R.A., and Bredt, D.S. (2002) Synaptic glutamate receptor clustering in mice lacking the SH3 and GK domains of SAP97. Eur. J. Neurosci. 16:1517-22.

196. Ito CY, Li CY, Bernstein, A., Dick, J.E., and Stanford, W.L. (2003) Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A null mice. Blood 101:517-523.

35

197. Taichman BD, Schachtner SK, Li Y, Puri MC, Bernstein, A., and Scott Baldwin H. (2003) A unique pattern of Tie1 expression in the developing murine lung. Exp. Lung Res. 29:113-22.

198. Nguyen, M.M., Nguyen, M.L., Caruana, G., Bernstein, A., Lambert, P.F., and Griep, A.E. (2003) Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol. Cell. Biol. 23: 8970-8981.

199. Ming-Tain, L., Chen, E., Ming-Chih, C., DiMuzio-Mower, J., Min, X., Qian, H., Price, E., Xia-Ping, S., Donoviel, D.B., Bernstein, A., Hazuda, D., Gardell, S.J., and Yue-Ming, L. Presenilin-1 and Presenilin-2 exhibit distinct yet overlapping γ-secretase activities. J. Biol. Chem. 278:22475-22481.

200. Puri, M. and Bernstein, A. (2003) Requirement for the TIE family of receptor tyrosine kinases in adult but not fetal hematopoiesis. Proc. Natl. Acad. Sci. U.S.A. 100:12753-12758.

201. Shivakrupa, R., Bernstein, A., Watring, N., and Linnekin, D. (2003) Phosphatidylinositol 3’-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 63:4412-4419.

202. Kimura, Y., Jones, N., Klüppel, M., Hirashima, M., Tachibana, K., Cohn, J.B., Wrana, J.L., Pawson, T., and Bernstein, A. (2004) Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc. Natl. Acad. Sci. U.S.A. 101:6015-6020.

203. Hirashima M., Bernstein A., Stanford W.L., Rossant J. (2004) Gene-trap expression screening to identify endothelial-specific genes. Blood. 104:711-718.

204. Tachibana, K., Jones N, Dumont DJ, Puri MC, Bernstein, A. (2005) Selective role of a distinct tyrosine residue on tie2 in heart development and early hematopoiesis. Mol Cell Biol. 25:4693-4702

205. Takeda T, Asahi M, Yamaguchi O, Hikoso S, Nakayama H, Kusakari Y, Kawai M, Hongo K, Higuchi Y, Kashiwase K, Watanabe T, Taniike M, Nakai A, Nishida K, Kurihara S, Donoviel DB, Bernstein A., Tomita T, Iwatsubo T, Hori M, Otsu K (2005) Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling. Faseb J. 19: 2069-2071.

206. Iijima T., Imai T., Kimura Y., Bernstein A., Okano HJ, Yuzaki M., Okano H. (2005) Hzf protein regulates dendritic localization and BDNF-induced translation of type 1 inositol 1,4,5-trisphosphate receptor mRNA. Proc Natl Acad Sci USA. 102:17190-17195.

207. Lai MT, Crouthamel MC, Dimuzio J., Pietrak BL, Donoviel DB, Bernstein A., Gardell SJ, Hazuda D (2006) A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage. J Neurochem. 96:118-125.

208. Naim E., Bernstein A., Bertram JF, Caruana G. (2005) Mutagenesis of the epithelial polarity gene, discs large 1, perturbs nephrogenesis in the developing mouse kidney. Kidney International 68:955-965.

209. Frese K.K., Latorre, I.J., Chung S.H., Caruana G., Bernstein A., Justice M.J., Jones S.N., Donehower L.A., Garner C.C., Javier R.T. (2006). Oncogenic Function for the Dlg1 Mammalian Homologue of the Drosophila Discs-Large Tumor Suppressor. EMBO J. 25:1406-17.

210. Alexson TO, Hitoshi S., Coles BL, Bernstein A., van der Kooy D. (2006). Notch signaling is required to maintain all neural stem cell populations—irrespective of spatial or temporal niche. Dev Neurosci. 28:34-48.

36

211. He G, Qing H, Cai F, Kwok C, Xu H, Yu G, Bernstein A., Song W (2006) Ubiquitin-proteasome pathway mediates degradation of APH-1. J Neurochem. 99: 1403-1412.

212. Frese KK, Latorre IJ, Chung SH, Caruana G, Bernstein A, Jones SN, Donehower LA, Justice MJ, Garner CC, Javier RT (2006) Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor. EMBO J. (2006) 25: 1406–1417.

213. Iijima T., Ogura H., Takatsuki K., Kawahara S., Wakabayashi K., Nakayama D., Fujioka M., Kimura Y., Bernstein A., Okano HJ., Kirino Y., Okano H. (2007) Impaired motor functions in mice lacking the RNA-binding protein Hzf. Neurosci Res. 58: 183-9.

214. Thornhill P.B., Cohn J.B., Drury G., Stanford W.L., Bernstein A., Desbarats J. (2007) A proteomic screen reveals novel Fas ligand interacting proteins within nervous system Schwann cells. FEBS, Letters 581(23): 4455-4462.

215. Das S., Raj L., Zhao Bo, Bernstein A., Kimura Y., Aaronson S.A., Lee S.W. (2007) Hzf Determines Cell Survival upon Genotoxic Stress by Modulating p53 Transactivation. Cell 130: 624-637.

216. Daar A.S., Singer PA., Persad DL., Pramming SK., Matthews DR., Beaglehole R., Bernstein A., Borysiewicz LK., Colagiuri S., Ganguly N., Glass RI., Finegood DT., Koplan J., Nabel EG., Sarna G., Sarrafzadegan N., Smith R., Yach D., Bell J.(2007) Grand challenges in chronic non-communicable diseases. Nature 450: 494-496.

217. Bernstein, A. (2007) Cancer stem cells: the centrality of translational research to cancer control. Canadian Medical Association Journal 176: 29-30.

218. Bernstein A. (2008) AIDS and the next 25 years. Science. 320: 717. 219. Bernstein A. (2008) An HIV/AIDS vaccine: where do we go from here? Trends in

Microbiology.16 : 553-554. Non-Scientific Publications and Articles: 1. Bernstein, A. (2001) Balancing act: Science and society. The Globe and Mail: February 14. 2. Bernstein, A. (2001) Virtual transformation. Canadian Chemical News: p. 17, May 2001. 3. Bernstein, A. (2001) Health research revolution : Innovation will shape this century. The

Toronto Star: November 8. 4. Bernstein, A. (2001) Health research will shape this century. Research Money 15:8. 5. Bernstein, A. (2002) Academic Health Sciences Centres: More important than ever in the

century of health research. Healthcare Papers 2:54-58. 6. Bernstein, A. (2002) Creating a framework for stem cell research in Canada.

BIOTECanada Insights: pp. 35-40, May 2002. 7. Bernstein, A. (2002) Creation of the CIHR : A genuine transformation in health research.

Hospital Quarterly 6:10-12. 8. Bernstein, A. (2002) CIHR transforms research in Canada. Hospital News: October 2002. 9. Bernstein, A. (2002) Canada: A world leader in health research and biotechnology. The

Hill Times: p. 25, November 4. 10. Bernstein, A. (2002) Turning research into action. Toronto Rehab: pp. 2-3, Fall 2002. 11. Bernstein, A. (2002) Reflections on Romanow. Hospital Quarterly 6(2):38. 12. Bernstein, A. (2003) Toward effective Canadian public-private partnerships in health

research. Canadian Medical Association Journal 168:288-289. 13. Bernstein, A. (2003) Health research: where health and innovation intersect. The Hill

Times: p. 39, March 17.

37

14. Bernstein, A. (2003) Striking a balance: An ethical response to the revolution in health research. In: Statistics, Science and Public Policy VII – Environment, Health and Globalization (A.M. Herzberg and I. Krupka, eds.), Queen’s University, Kingston, pp. 171-179.

15. Bernstein, A. (2003) SARS: Or what you don’t know can hurt you. The Hill Times: p. 13, May 12.

16. Bernstein, A. (2003) Get ready for the next SARS. The Globe and Mail: June 19. 17. Bernstein, A. (2003) SRAS: il y aura une prochaine fois. Le Devoir: July 4. 18. Bernstein, A. (2003) Canadian Institutes of Health Research budgetary dilemma:

Unprecedented growth and program reductions. Canadian Medical Association Journal 169(6):567-568.

19. Bernstein, A. (2003) CIHR and health research: exceptional value. The Hill Times: p. 22, October 20.

20. Bernstein, A. (2003) SARS: Make no mistake – there will be a next time. Hospital Quarterly 6(4):21-22.

21. Bernstein, A. (2003) Fuelling pipeline of health innovation. The Hill Times: p. 22, November 3

22. Bernstein, A. (2003) The future of health research: CIHR and youth / L’avenir de la recherché en santé: les IRSC et les jeunes. Future Health / Perspective Santé (Canadians for Health Research/Les Canadiens pour la recherche médicale: pp. 4-6, Autumn/automne 2003.

23. Bernstein, A. (2004) CIHR: Positioning Canada as a country of excellence in health research and innovation, the only way to go. The Hill Times: p. 30, February 2

24. Bernstein, A. (2004) Health-Care Diagnosis, More knowledge needed. The Globe and Mail: p. A17, September 14.

25. Bernstein, A., Moher, D. (2004) Registering CIHR-funded randomized controlled trials: a global public good. Canadian Medical Association Journal. 171: 4-6.

26. Bernstein, A., (2004) Fuelling the biotech pipeline – After 30 years, advances in recombinant DNA technology is finally starting to pay off. The Hill Times: p. 17, November 1-7.

27. Bernstein, A., (2005) Le Sommet du G8 Investir dans la santé africaine Le Devoir 6 juillet. 28. Bernstein, A., (2005) G-8 Summit: Best investment is in Africa’s health Toronto Star July 5. 29. Bernstein, A., (2005) New ethical requirements at the NIH: implications for CIHR and

Canada. Canadian Medical Association Journal, 173: 353-354. 30. Bernstein, A., (2005) The Commitment to Knowledge Transfer: The Launch of a new

journal reinforces the commitment to disseminating new thinking and ideas. Healthcare Policy, 1:1 18-19

31. Bernstein, A. (2006) Access to care: the catalytic role of health research. The Hill Times: p. 24, February 13

32. Bernstein, A. (2006) The promise of the health sciences in the 21st century. Can J. Nurs Leadersh., 18(4): 41-3

33. Bernstein, A. (2006) The promise of the health sciences in the 21st century. Healthc Q.., 9(1): 8-9

34. Bernstein, A. (2006) Un système de soins de santé digne du 21e siècle. Découvrir,27(4): 5

38

35. Bernstein, A. (2006) Opinion Leader: CIHR President comments on panel report. Research Money, 20(11): 8

36. Bernstein, A. (2006) Publicly-funded research and innovation: Canada’s key to the 21st Century. The Hill Times: p 36-37, November 6

37. Bernstein, A. , Graham, Ian (2007) Health Research: an excuse not to act or a catalyst for change. The Hill Times: p.30, February 12

38. Bernstein, A., Graham, Ian (2007) Le Canada, une superpuissance dans les domaines de la santé et des sciences. Le Devoir, May 18

39. Bernstein, A. (2007) We’re in a global race with no finish line. The Globe and Mail: p.A15, May 23

40. Bernstein, A. (2007) Stepping Down from the CIHR. Science: 317:1035 41. Bernstein, A. (2007) Stepping Down from CIHR. Canadian Medical Association Journal.

177(6): 605-606. 42. Bernstein, A. (2009) Politicians must open the tent to scientists. The Globe and Mail: A17,

March 24.